Instructions for use
The following coverage policy applies to health benefit plans administered by Cigna. Coverage policies are intended to provide guidance in interpreting certain standard Cigna benefit plans and are used by medical directors and other health care professionals in making medical necessity and other coverage determinations. Please note the terms of a customer’s particular benefit plan document may differ significantly from the standard benefit plans upon which these coverage policies are based. For example, a customer’s benefit plan document may contain a specific exclusion related to a topic addressed in a coverage policy.

In the event of a conflict, a customer’s benefit plan document always supersedes the information in the coverage policy. In the absence of federal or state coverage mandates, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of:

1. The terms of the applicable benefit plan document in effect on the date of service
2. Any applicable laws and regulations
3. Any relevant collateral source materials including coverage policies
4. The specific facts of the particular situation

Coverage policies relate exclusively to the administration of health benefit plans. Coverage policies are not recommendations for treatment and should never be used as treatment guidelines.

This evidence-based medical coverage policy has been developed by eviCore, Inc. Some information in this coverage policy may not apply to all benefit plans administered by Cigna.

These guidelines include procedures eviCore does not review for Cigna. Please refer to the Cigna CPT code list for the current list of high-tech imaging procedures that eviCore reviews for Cigna.

CPT® (Current Procedural Terminology) is a registered trademark of the American Medical Association (AMA). CPT® five digit codes, nomenclature and other data are copyright 2017 American Medical Association. All Rights Reserved. No fee schedules, basic units, relative values or related listings are included in the CPT® book. AMA does not directly or indirectly practice medicine or dispense medical services. AMA assumes no liability for the data contained herein or not contained herein.
<table>
<thead>
<tr>
<th>Abdomen Imaging Guidelines</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abbreviations for Abdomen Imaging Guidelines</td>
<td>4</td>
</tr>
<tr>
<td>AB-1: General Guidelines</td>
<td>6</td>
</tr>
<tr>
<td>AB-2: Abdominal Pain</td>
<td>12</td>
</tr>
<tr>
<td>AB-3: Abdominal Sepsis (Suspected Abdominal Abscess)</td>
<td>20</td>
</tr>
<tr>
<td>AB-4: Flank Pain, Rule Out or Known Renal/Ureteral Stone</td>
<td>22</td>
</tr>
<tr>
<td>AB-5: Gastroenteritis</td>
<td>26</td>
</tr>
<tr>
<td>AB-6: Mesenteric/Colonic Ischemia</td>
<td>28</td>
</tr>
<tr>
<td>AB-7: Post-Operative Pain With-in 60 Days Following Abdominal Surgery – Abdominal Procedure</td>
<td>31</td>
</tr>
<tr>
<td>AB-8: Abdominal Lymphadenopathy</td>
<td>33</td>
</tr>
<tr>
<td>AB-9: Bariatric Surgery</td>
<td>36</td>
</tr>
<tr>
<td>AB-10: Blunt Abdominal Trauma</td>
<td>38</td>
</tr>
<tr>
<td>AB-11: Gaucher’s Disease and Hemochromatosis</td>
<td>40</td>
</tr>
<tr>
<td>AB-12: Hernias</td>
<td>43</td>
</tr>
<tr>
<td>AB-13: Abdominal Mass</td>
<td>46</td>
</tr>
<tr>
<td>AB-14: Lower Extremity Edema</td>
<td>48</td>
</tr>
<tr>
<td>AB-15: Zollinger-Ellison Syndrome (ZES)</td>
<td>49</td>
</tr>
<tr>
<td>AB-16: Adrenal Cortical Lesions</td>
<td>51</td>
</tr>
<tr>
<td>AB-17: Abdominal Aortic Aneurysm (AAA), Iliac Artery Aneurysm (IAA), and Visceral Artery Aneurysms Follow-Up of Known Aneurysms and Pre-Op Evaluation</td>
<td>58</td>
</tr>
<tr>
<td>AB-18: Abdominal Aortic Aneurysm (AAA) and Iliac Artery Aneurysm (IAA)-Post Endovascular or Open Aortic Repair</td>
<td>60</td>
</tr>
<tr>
<td>AB-19: Aortic Dissection and Imaging for Other Aortic Conditions</td>
<td>62</td>
</tr>
<tr>
<td>AB-20: Bowel Obstruction and Gastroparesis</td>
<td>64</td>
</tr>
<tr>
<td>AB-21: Diarrhea, Constipation, and Irritable Bowel</td>
<td>66</td>
</tr>
<tr>
<td>AB-22: GI Bleeding</td>
<td>71</td>
</tr>
<tr>
<td>AB-23: Inflammatory Bowel Disease</td>
<td>74</td>
</tr>
<tr>
<td>Rule Out Crohn’s Disease or Ulcerative Colitis</td>
<td>74</td>
</tr>
<tr>
<td>AB-24: Celiac Disease (SPRUE)</td>
<td>78</td>
</tr>
<tr>
<td>AB-25: CT Colonography (CTC)</td>
<td>80</td>
</tr>
<tr>
<td>AB-26: Cirrhosis and Liver Screening for Hepatocellular Carcinoma (HCC); Ascites and Portal Hypertension</td>
<td>82</td>
</tr>
<tr>
<td>AB-27: MR Cholangiopancreatography (MRCP)</td>
<td>87</td>
</tr>
<tr>
<td>AB-28: Biliary Tract Disease Jaundice</td>
<td>89</td>
</tr>
<tr>
<td>AB-29: Liver Lesion Characterization</td>
<td>92</td>
</tr>
<tr>
<td>AB-30: Elevated Liver Function (LFT) Levels</td>
<td>96</td>
</tr>
<tr>
<td>AB-31: Pancreatic Lesion</td>
<td>99</td>
</tr>
<tr>
<td>AB-32: Pancreatic Pseudocysts</td>
<td>103</td>
</tr>
<tr>
<td>AB-33: Pancreatitis</td>
<td>105</td>
</tr>
<tr>
<td>AB-34: Spleen</td>
<td>108</td>
</tr>
<tr>
<td>AB-35: Indeterminate Renal Lesion</td>
<td>111</td>
</tr>
<tr>
<td>AB-36: Renal Failure</td>
<td>116</td>
</tr>
<tr>
<td>AB-37: Renovascular Hypertension</td>
<td>118</td>
</tr>
<tr>
<td>AB-38: Polycystic Kidney Disease</td>
<td>120</td>
</tr>
<tr>
<td>AB-39: Hematuria and Hydronephrosis</td>
<td>122</td>
</tr>
<tr>
<td>AB-40: Urinary Tract Infection (UTI)</td>
<td>125</td>
</tr>
<tr>
<td>AB-41: Patent Urachus</td>
<td>127</td>
</tr>
<tr>
<td>AB-42: Transplant</td>
<td>129</td>
</tr>
<tr>
<td>AB-43: Hepatic and Abdominal Arteries</td>
<td>134</td>
</tr>
<tr>
<td>AB-44: This section intentionally left blank</td>
<td>137</td>
</tr>
<tr>
<td>AB-45: Liver Elastography</td>
<td>138</td>
</tr>
</tbody>
</table>
## Abbreviations for Abdomen Imaging Guidelines

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>AAA</td>
<td>abdominal aortic aneurysm</td>
</tr>
<tr>
<td>AASLD</td>
<td>American Association for the Study of Liver Diseases</td>
</tr>
<tr>
<td>ACE</td>
<td>angiotensin-converting enzyme</td>
</tr>
<tr>
<td>ACG</td>
<td>American College of Gastroenterology</td>
</tr>
<tr>
<td>ACR</td>
<td>American College of Radiology</td>
</tr>
<tr>
<td>ACTH</td>
<td>adrenocorticotropic hormone</td>
</tr>
<tr>
<td>AFP</td>
<td>alpha-fetoprotein</td>
</tr>
<tr>
<td>AGA</td>
<td>American Gastroenterological Association</td>
</tr>
<tr>
<td>ALT</td>
<td>alanine aminotransferase</td>
</tr>
<tr>
<td>ASGE</td>
<td>American Society for Gastrointestinal Endoscopy</td>
</tr>
<tr>
<td>AST</td>
<td>aspartate aminotransferase</td>
</tr>
<tr>
<td>AUA</td>
<td>American Urological Association</td>
</tr>
<tr>
<td>BEIR</td>
<td>Biological Effects of Ionizing Radiation</td>
</tr>
<tr>
<td>BUN</td>
<td>blood urea nitrogen</td>
</tr>
<tr>
<td>CAG</td>
<td>Canadian Association of Gastroenterology</td>
</tr>
<tr>
<td>CNS</td>
<td>central nervous system</td>
</tr>
<tr>
<td>CT</td>
<td>computed tomography</td>
</tr>
<tr>
<td>CTA</td>
<td>computed tomography angiography</td>
</tr>
<tr>
<td>CTC</td>
<td>computed tomography colonography (aka: virtual colonoscopy)</td>
</tr>
<tr>
<td>DVT</td>
<td>deep vein thrombosis</td>
</tr>
<tr>
<td>ERCP</td>
<td>endoscopic retrograde cholangiopancreatography</td>
</tr>
<tr>
<td>FNH</td>
<td>focal nodular hyperplasia</td>
</tr>
<tr>
<td>GFR</td>
<td>glomerular filtration rate</td>
</tr>
<tr>
<td>GGT</td>
<td>gamma glutamyltransferase</td>
</tr>
<tr>
<td>GI</td>
<td>gastrointestinal</td>
</tr>
<tr>
<td>HCC</td>
<td>hepatocellular carcinoma</td>
</tr>
<tr>
<td>HCPCS</td>
<td>Healthcare Common Procedural Coding System (commonly pronounced: “hix pix”)</td>
</tr>
<tr>
<td>HU</td>
<td>Hounsfield units</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Description</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------</td>
</tr>
<tr>
<td>IAA</td>
<td>iliac artery aneurysm</td>
</tr>
<tr>
<td>IV</td>
<td>intravenous</td>
</tr>
<tr>
<td>KUB</td>
<td>kidneys, ureters, bladder (plain frontal supine abdominal radiograph)</td>
</tr>
<tr>
<td>LFT</td>
<td>liver function tests</td>
</tr>
<tr>
<td>MRCP</td>
<td>magnetic resonance cholangiopancreatography</td>
</tr>
<tr>
<td>MRA</td>
<td>magnetic resonance angiography</td>
</tr>
<tr>
<td>MRI</td>
<td>magnetic resonance imaging</td>
</tr>
<tr>
<td>mSv</td>
<td>millisievert</td>
</tr>
<tr>
<td>NAFLD</td>
<td>nonalcoholic fatty liver disease</td>
</tr>
<tr>
<td>PA</td>
<td>posteroanterior projection</td>
</tr>
<tr>
<td>PET</td>
<td>positron emission tomography</td>
</tr>
<tr>
<td>RAS</td>
<td>renal artery stenosis</td>
</tr>
<tr>
<td>RBC</td>
<td>red blood cell</td>
</tr>
<tr>
<td>SBFT</td>
<td>small bowel follow through</td>
</tr>
<tr>
<td>SPECT</td>
<td>single photon emission computed tomography</td>
</tr>
<tr>
<td>VC</td>
<td>virtual colonoscopy (CT colonography)</td>
</tr>
<tr>
<td>PFT</td>
<td>pulmonary function tests</td>
</tr>
<tr>
<td>WBC</td>
<td>white blood cell</td>
</tr>
<tr>
<td>ZES</td>
<td>Zollinger-Ellison Syndrome</td>
</tr>
</tbody>
</table>
## AB-1: General Guidelines

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>AB-1.1: Overview</td>
<td>7</td>
</tr>
<tr>
<td>AB-1.2: CT Imaging</td>
<td>7</td>
</tr>
<tr>
<td>AB-1.3: MR Imaging</td>
<td>8</td>
</tr>
<tr>
<td>AB-1.4: MR Enterography Coding Notes</td>
<td>8</td>
</tr>
<tr>
<td>AB-1.5: Ultrasound</td>
<td>9</td>
</tr>
<tr>
<td>AB-1.6: Abdominal Ultrasound</td>
<td>9</td>
</tr>
<tr>
<td>AB-1.7: Retroperitoneal Ultrasound</td>
<td>10</td>
</tr>
<tr>
<td>AB-1.8: This section intentionally left blank</td>
<td>10</td>
</tr>
<tr>
<td>AB-1.9: Contrast-Enhanced Ultrasound</td>
<td>10</td>
</tr>
<tr>
<td>AB-1.10: Special Considerations</td>
<td>11</td>
</tr>
</tbody>
</table>
**AB-1.1: Overview**

- A current clinical evaluation (within 60 days) is generally required before advanced imaging can be considered. The clinical evaluation may include a relevant history and physical examination, appropriate laboratory studies, and non-advanced imaging modalities such as plain X-ray or ultrasound. Other meaningful contact (telephone call, electronic mail or messaging) by an established individual can substitute for a face-to-face clinical evaluation.

- GI Specialist evaluations can be helpful, particularly in determining mesenteric/colonic ischemia, diarrhea/constipation, irritable bowel syndrome (IBS), or need for MRCP.

- Conservative treatment for abdominal pain can include (list is not exhaustive):
  - Anti-secretory or H. Pylori medications
  - Non-steroidal or opiate analgesia
  - Plain abdominal radiography
  - Diet modification
  - Pro- or anti-motility agents

- Abdominal imaging begins at the diaphragm and extends to the umbilicus or iliac crest.

- Pelvic imaging begins at the iliac crest and extends to the pubis.

- Clinical concerns at the dividing line can be providers’ choice (abdomen and pelvis; abdomen or pelvis).

**AB-1.2: CT Imaging**

- CT imaging is a more generalized modality. Abdominal CT is usually performed with contrast (CPT® 74160):
  - Oral contrast has no relation to the IV contrast administered.
  - Exceptions are noted in these guidelines, and include:
    - Abdominal CT with contrast (CPT® 74160) or without and with contrast (CPT® 74170) with suspicion of a solid organ lesion (liver, kidney, pancreas, spleen).
    - Abdominal CT without contrast (CPT® 74150) or Abdomen and Pelvis CT (CPT® 74176) if there is renal insufficiency/failure, or a documented allergy to contrast. It can also be considered for diabetics or the very elderly.
  - Abdomen with Pelvis CT, usually with contrast (CPT® 74177), should be considered when signs or symptoms are generalized, or involve a lower quadrant of the abdomen.
  - CT Enterography (CPT® 74177) combines CT imaging with large volumes of ingested neutral bowel contrast material to allow visualization of the small bowel.
    - Usually, only 2D reformatting is used (coronal reformatted images);
    - If the 3D rendering codes are requested (CPT® 76376 or CPT® 76377), then the final radiology report should be obtained first to verify that true 3D rendering was performed.

- See AB-23: Inflammatory Bowel Disease Rule Out Crohn’s Disease or Ulcerative Colitis
CT Enteroclysis
- A tube is placed through the nose or mouth and advanced into the duodenum or jejunum. Bowel contrast material is infused through the tube and CT imaging is performed either with or without intravenous contrast.
- CT enteroclysis is used to allow visualization of the small bowel wall and lumen. CT enteroclysis may allow better or more consistent distention of the small bowel than CT enterography.
- Report by assigning: CPT® 74176 or CPT® 74177
- Usually, only 2D reformating is used (coronal reformatted images).
- The final radiology report should be obtained first to verify that true 3D rendering was performed when 3D rendering codes are requested (CPT® 76376 or CPT® 76377).
- See AB-23: Inflammatory Bowel Disease Rule Out Crohn’s Disease or Ulcerative Colitis

Triple-phase CT
- 3 phases of a triple-phase CT are:
  1) a hepatic arterial phase,
  2) a portal venous phase, and
  3) a washout or delayed acquisitions phase.
- It should be noted that, in general, a precontrast or noncontrast CT is generally not needed, except in those individuals previously treated with locoregional embolic or ablative therapies. Thus, for the evaluation of liver lesions EITHER a CT abdomen with contrast (CPT® 74160) or CT abdomen without and with contrast (CPT® 74170) can be approved. This is in contradistinction to MRI, in which precontrast imaging is needed.

AB-1.3: MR Imaging
- MRI may be preferred as a more targeted study in cases of renal failure in individuals allergic to intravenous CT contrast, and as noted in these guidelines.
- MRI of the abdomen with contrast only is essentially never performed. If contrast is indicated, MRI Abdomen without and with contrast (CPT® 74183) should be performed.
- For pregnant women ultrasound or MRI without contrast should be used to avoid radiation exposure. The use of gadolinium contrast agents is contraindicated during pregnancy, as gadolinium contrast agents cross the placenta and enter the amniotic fluid with unknown long term effects on the fetus.

AB-1.4: MR Enterography Coding Notes
- MRI Enterography is reported in one of two ways:
  - MRI Abdomen without and with contrast (CPT® 74183), or
  - MRI Abdomen without and with contrast (CPT® 74183) and MRI Pelvis with and without contrast (CPT® 72197)
AB-1.5: Ultrasound

Ultrasound, also called sonography, uses high frequency sounds waves to image body structures.

- The routine use of 3D and 4D rendering, (post-processing), in conjunction with ultrasound is considered investigational.
- All ultrasound studies require permanently recorded images either stored on film or in a Picture Archiving and Communication System (PACS).
- The use of a hand-held or any Doppler device that does not create a hard-copy output is considered part of the physical examination and is not separately billable. This exclusion includes devices that produce a record that does not permit analysis of bi-directional vascular flow.

Duplex scan describes an ultrasonic scanning procedure for characterizing the pattern and direction of blood flow in arteries and veins with the production of real-time images integrating B-mode 2D vascular structures, Doppler spectral analysis, and color flow Doppler imaging.

- The minimal use of color Doppler alone, when performed for anatomical structure identification during a standard ultrasound procedure, is not separately reimbursable.

AB-1.6: Abdominal Ultrasound

Complete abdominal ultrasound (CPT® 76700) includes all of the following required elements:

- Liver, gallbladder, common bile duct, pancreas, spleen, kidneys, upper abdominal aorta, and inferior vena cava.
- If a particular structure or organ cannot be visualized, the report should document the reason.

Limited abdominal ultrasound (CPT® 76705) is without all of these required elements and can refer to a specific study of a single organ, a limited area of the abdomen, or a follow-up study.

Further, CPT® 76705 should:
- Be assigned to report follow-up studies once a complete abdominal ultrasound (CPT® 76700) has been performed; and
- Be assigned to report ultrasonic evaluation of diaphragmatic motion; and
- Be reported only once per individual imaging session; and
  - Not be reported with CPT® 76700 for the same individual for the same imaging session.
AB-1.7: Retroperitoneal Ultrasound

- Complete retroperitoneal ultrasound (CPT® 76770) includes all of the following required elements:
  - Kidneys, lymph nodes, abdominal aorta, common iliac artery origins, inferior vena cava.
  - For urinary tract indications, a complete study can consist of kidneys and bladder.

- Limited retroperitoneal ultrasound (CPT® 76775) studies are without all of these required elements and can refer to a specific study of a single organ, a limited area of the abdomen, or a follow-up study.
  - Further, CPT® 76775 should:
    - Be assigned to report follow-up studies once a complete retroperitoneal ultrasound (CPT® 76770) has been performed; and
    - Be reported only once per individual imaging session; and
    - Not be reported with CPT® 76770 for the same individual for the same imaging session.

AB-1.8: This section intentionally left blank

AB-1.9: Contrast-Enhanced Ultrasound

Ultrasound with contrast (CEUS, CPT® 76978, CPT® 76979) is only considered when MRI or CT cannot be performed, and the clinical situation requires ultrasound contrast to further delineate the nature of the lesion. CEUS of the liver is otherwise considered investigational or experimental at this time.
**AB-1.10: Special Considerations**

- CT of the Abdomen and Pelvis either with or without contrast (CPT® 74177 or CPT® 74176) can be performed prior to endoscopy if requested by the physician who will be performing the endoscopy, especially if there is suspected inflammatory bowel disease.

- Persistent unexplained nausea and vomiting:
  - One non-contrast brain MRI (CPT® 70551) can be performed in individual with persistent, unexplained nausea and vomiting and a negative GI evaluation.
  - See **HD-1.7: General Guidelines – Other Imaging Situations** in the Head Imaging Guidelines.

- Fever of unknown origin; unexplained weight loss
  - See **ONC-30: Medical Conditions with Cancer in the Differential Diagnosis** in the Oncology Imaging Guidelines.

- Suspected ascites should be initially evaluated by ultrasound.
  - Ultrasound (CPT® 76700 or CPT® 76705) results can then determine the need for peritoneal fluid analysis or further imaging specific to the findings.\(^3\)\(^4\)

**References**


## AB-2: Abdominal Pain

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>AB-2.1: General Information</td>
<td>13</td>
</tr>
<tr>
<td>AB-2.2: Abdominal Pain</td>
<td>14</td>
</tr>
<tr>
<td>AB-2.3: Right Upper Quadrant Pain including Suspected Gallbladder Disease</td>
<td>16</td>
</tr>
<tr>
<td>AB-2.4: Left Upper Quadrant (LUQ) Pain</td>
<td>16</td>
</tr>
<tr>
<td>AB-2.5: Epigastric Pain and Dyspepsia</td>
<td>18</td>
</tr>
</tbody>
</table>
**AB-2.1: General Information**
The tables in **AB-2.2: Abdominal Pain** provide imaging guidance for generalized and quadrant specific abdominal pain. The column headers are defined as the following:

<table>
<thead>
<tr>
<th>Pain Location</th>
<th>Initial Ultrasound?</th>
<th>Conservative Treatment?</th>
<th>Advanced Imaging Indicated?</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Location/type of abdominal pain</td>
<td>Is an initial US required before advanced imaging?</td>
<td>Is conservative treatment required before advanced imaging?</td>
<td>Advanced imaging indicated for the specific abdominal pain</td>
<td>Additional comments related to indication</td>
</tr>
</tbody>
</table>

**Red Flag Signs and Symptoms**
- In “red flag” situations, the imaging indications may vary from the usual imaging pathway. A red flag situation is described as the following:
  - Persistent abdominal pain and at least one of the following:
    - Failure of conservative treatment for 4 weeks
    - Cancer history
    - Fever (101 degrees or greater)
    - Mass
    - GI bleeding
    - Moderate to severe abdominal tenderness
    - Guarding, rebound tenderness, or other peritoneal signs
    - Elevated WBC as per the testing laboratory’s range
    - History of bariatric surgery
- Please note, that when any one red flag is present with abdominal pain, the initial ultrasound is not required. Please proceed to the imaging indications under the “Advanced Imaging” column.

**Pregnant Women**
- Abdominal US (CPT® 76700), and/or Pelvic US (if below the umbilicus) (CPT® 76856) and/or TV US (CPT® 76830) should be performed first. If ultrasound is equivocal or red flags are present, proceed to:
  - MRI abdomen without contrast (CPT® 74181) and/or MRI Pelvis without contrast (CPT® 72195) (if below the umbilicus).
# AB-2.2: Abdominal Pain

<table>
<thead>
<tr>
<th>Pain Location</th>
<th>Initial Ultrasound?</th>
<th>Conservative Treatment?</th>
<th>Advanced Imaging Indicated?</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Generalized, men and also women not of childbearing age</td>
<td>Yes Complete or limited abdomen</td>
<td>No*</td>
<td>*If equivocal ultrasound or if pain is accompanied with: any one red flag ▶ CT Abdomen and Pelvis with contrast</td>
<td>See red flags in AB-2.1</td>
</tr>
<tr>
<td>Generalized, women of childbearing age, not pregnant</td>
<td>Yes Complete abdomen and/or transvaginal and/or complete pelvis</td>
<td>No*</td>
<td>*If equivocal ultrasound or if pain is accompanied with any one red flag: ▶ CT Abdomen and Pelvis with contrast or ▶ MRI Abdomen and/or Pelvis without and with contrast</td>
<td>See red flags in AB-2.1 See imaging for pregnant women in AB-2.1</td>
</tr>
<tr>
<td>Generalized, pregnant</td>
<td>Yes Complete abdomen and/or transvaginal and/or complete pelvis</td>
<td>No</td>
<td>▶ If ultrasound is equivocal with acute pain or any one red flag, MRI Abdomen and/or Pelvis without contrast. ▶ In carefully selected individuals where CT imaging may be considered life saving for the mother, it can be safely performed with careful attention to radiation protection and technique. Requests for CT should go to MD for review.</td>
<td>See red flags in AB-2.1 and imaging for pregnant women in AB-2.1</td>
</tr>
<tr>
<td>Left Lower Quadrant, rule out diverticulitis – ALL men and non-pregnant women</td>
<td>No</td>
<td>No</td>
<td>▶ CT Abdomen and Pelvis with contrast</td>
<td>See imaging for pregnant women in AB-2.1</td>
</tr>
<tr>
<td>Left Lower Quadrant, suspected or known intraabdominal abscess – ALL men and non-pregnant women</td>
<td>No</td>
<td>No</td>
<td>If fever or elevated WBC, then CT Abdomen and/or Pelvis with contrast.</td>
<td>See imaging for pregnant women in AB-2.1 See AB-3-Abdominal Sepsis (Suspected Abdominal Abscess)</td>
</tr>
<tr>
<td>Pain Location</td>
<td>Initial Ultrasound?</td>
<td>Conservative Treatment</td>
<td>Advanced Imaging Indicated?</td>
<td>Comments</td>
</tr>
<tr>
<td>---------------</td>
<td>---------------------</td>
<td>------------------------</td>
<td>----------------------------</td>
<td>----------</td>
</tr>
</tbody>
</table>
| Left Lower Quadrant, follow-up known intraabdominal abscess – ALL men and non-pregnant women | No | No | Serial abdominal and/or pelvic ultrasound (CPT®76700 and/or CPT®76856) or CT Abdomen and/or Pelvis with contrast:  

- The interval can be days, weeks, or months | See imaging for pregnant women in AB-2.1  

- See **AB-3-Abdominal Sepsis (Suspected Abdominal Abscess)** |
| Left Upper Quadrant – ALL men and non-pregnant women | See **AB-2.4 Left Upper Quadrant (LUQ) Pain** | See **AB-2.4 Left Upper Quadrant (LUQ) Pain** | See **AB-2.4 Left Upper Quadrant (LUQ) Pain** | See imaging for pregnant women in: AB-2.1 |
| Right Lower Quadrant, rule out appendicitis in – ALL men and non-pregnant women | Ultrasound may be performed but is not required prior to performing a CT of the Abdomen and Pelvis with contrast or without contrast. | No | CT Abdomen and Pelvis either with contrast or without contrast. | See imaging for pregnant women in: AB-2.1 |
| Right Upper Quadrant, rule out cholecystitis - ALL men and non-pregnant women | See **AB-2.3: Right Upper Quadrant Pain including Suspected Galbladder Disease** | See **AB-2.3: Right Upper Quadrant Pain including Suspected Galbladder Disease** | See **AB-2.3: Right Upper Quadrant Pain including Suspected Galbladder Disease** | See imaging for pregnant women in AB-2.1 |
| Epigastric pain, dyspepsia, gastritis, and postprandial fullness – ALL men and non-pregnant women | See **AB-2.5: Epigastric Pain and Dyspepsia** | See **AB-2.5: Epigastric Pain and Dyspepsia** | See **AB-2.5: Epigastric Pain and Dyspepsia** | See imaging for pregnant women in AB-2.1 |
| Acute epigastric pain with any red flag symptoms – ALL men and non-pregnant women | See **AB-2.5: Epigastric Pain and Dyspepsia** | See **AB-2.5: Epigastric Pain and Dyspepsia** | See **AB-2.5: Epigastric Pain and Dyspepsia** | See imaging for pregnant women in AB-2.1 |
### CPT® Codes for AB 2.2

<table>
<thead>
<tr>
<th>CPT® Code</th>
<th>Description</th>
<th>CPT® Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>74150</td>
<td>CT Abdomen without contrast</td>
<td>76700</td>
<td>Ultrasound, complete Abdomen</td>
</tr>
<tr>
<td>74160</td>
<td>CT Abdomen with contrast</td>
<td>76705</td>
<td>Ultrasound, limited Abdomen</td>
</tr>
<tr>
<td>74176</td>
<td>CT Abdomen and Pelvis without contrast</td>
<td>76830</td>
<td>Ultrasound, Transvaginal</td>
</tr>
<tr>
<td>74177</td>
<td>CT Abdomen and Pelvis with contrast</td>
<td>76856</td>
<td>Ultrasound, complete Pelvis</td>
</tr>
<tr>
<td>74181</td>
<td>MRI Abdomen without contrast</td>
<td>72195</td>
<td>MRI Pelvis without contrast</td>
</tr>
<tr>
<td>74183</td>
<td>MRI Abdomen without and with contrast</td>
<td>72197</td>
<td>MRI Pelvis without and with contrast</td>
</tr>
</tbody>
</table>

### AB-2.3: Right Upper Quadrant Pain including Suspected Gallbladder Disease

- For Pregnant Women, refer to **AB-2.1: General Information**
- For all others:
  - Abdominal US (complete or limited) is the initial diagnostic test in the absence of red flags
  - CT abdomen with contrast, or MRI abdomen without or without and with contrast if US is equivocal or red flags present

### AB-2.4: Left Upper Quadrant (LUQ) Pain

- Most common causes which may be more specifically evaluated:
  - Splenic etiologies:
    - Suspected trauma, or splenomegaly
      - See **AB-34: Spleen**
    - Suspected infarct or abscess (severe pain and tenderness, fever, history of atrial fibrillation)
      - CT Abdomen without and with contrast or with contrast (CPT® 74170 or CPT® 74160)
  - Pancreatic etiologies:
    - Suspected pancreatitis
      - See **AB-33.1: Pancreatitis**
  - Renal etiologies
    - Suspected nephrolithiasis
      - See **AB-4.1: Suspected Renal Stone**
    - Suspected pyelonephritis or abscess
- See **AB-40.1: Upper (Pyelonephritis)**
  - Suspected small or large bowel etiologies (e.g., ischemia, obstruction, volvulus, diverticulitis, mesenteric adenitis)
    - CT Abdomen (CPT® 74160) or CT Abdomen and Pelvis (CPT® 74177)
  - Gastric etiologies
    - If there is concern for peptic ulcer disease, or if the complaint is dyspepsia, without any red flags suggesting possible perforation or penetration, endoscopy would be the best study for assessing these potential conditions.
    - If there is concern for a more urgent gastric problem, such as perforation, or any red flag is present, then a CT Abdomen (CPT® 74160) or CT Abdomen and Pelvis (CPT® 74177) can be approved.
  - Suspected aortic dissection
    - See **PV-6.7: Aortic Dissection and Other Aortic Conditions**
  - Unknown etiology, simply reported as LUQ pain
    - LUQ pain with any red flag: A CT Abdomen or CT Abdomen and Pelvis (CPT® 74160 or CPT® 74177) can be approved.
    - LUQ pain without any red flags
      - Prior to advanced imaging, an adequate history and physical examination, with lab work to include: CBC, chemistry profile including electrolytes, BUN, creatinine, LFTs (ALT, AST, alkaline phosphatase and bilirubin) lipase, amylase, and urinalysis, should be performed with the intention of trying to establish a potential etiology.
      - If these evaluations and lab studies are negative or inconclusive for establishing a potential etiology which can be more specifically evaluated as described above, a CT Abdomen or CT Abdomen and Pelvis (CPT® 74160 or CPT® 74177) can be approved.

**Background and Supporting Information**

- LUQ pain is more difficult to categorize with regards to imaging as there are many potential etiologies, which might be better evaluated with different imaging procedures.
AB-2.5: Epigastric Pain and Dyspepsia

Epigastric pain with red flags: (non-pregnant individuals)
- Any of the following:
  - US abdomen (CPT® 76700 or CPT® 76705)
  - CT abdomen with contrast (CPT® 74160)
  - MRI abdomen with and without contrast (CPT® 74183)

Epigastric pain without red flags and dyspepsia
(Note: Those individuals with abnormal laboratory tests or physical findings should also be assessed under the appropriate guidelines for those findings, e.g. LFTs, jaundice, etc.)
- US abdomen (CPT® 76700 or CPT® 76705) to assess for biliary/pancreatic disease
- CT abdomen (CPT® 74160) or MRI abdomen (CPT® 74183), or MRCP (CPT® 74181 or CPT® 74183), may be appropriate to evaluate positive findings on US. The use of these advanced imaging procedures to evaluate the US findings may be specifically addressed in the dedicated guideline. For example, the use of MRCP to evaluate potential pathology in the biliary tree or pancreatic duct is addressed in AB-27: MR Cholangiopancreatography (MRCP)
- CT abdomen CPT® 74160, or MRI abdomen CPT® 74183 for persistent symptoms after a negative or inconclusive upper gastrointestinal endoscopy and ultrasound as well as one of the following:
  - Test and treat for Helicobacter pylori (H. pylori) and a trial of acid suppression with a proton pump inhibitor (PPI) for 4–8 weeks if eradication is successful, but symptoms do not resolve OR
  - An empiric trial of acid suppression with a PPI for 4–8 weeks

NOTE: See imaging for pregnant women AB-2.1: General Information

Background and Supporting Information
Epigastric pain without red flags and dyspepsia: defined by the ACG and CAG as predominant epigastric pain lasting at least one month and can be associated with any upper gastrointestinal symptoms such as epigastric fullness, nausea, vomiting, or heartburn
References


AB-3: Abdominal Sepsis (Suspected Abdominal Abscess)

AB-3.1: Abdominal Sepsis
**AB-3.1: Abdominal Sepsis**

- CT Abdomen and/or Pelvis with contrast (CPT® 74160, or CPT® 72193, or CPT® 74177) for abdominal symptoms associated with fever and/or elevated white blood cell count.¹

- CT Abdomen and Pelvis with contrast (CPT® 74177) interval imaging for intraperitoneal abscess.

- Serial Ultrasound (CPT® 76705) or CT with contrast (CPT® 74160, or CPT® 72193, or CPT® 74177) studies may be performed for follow-up of known abnormal fluid collections, especially following catheter drainage. The interval can be days, weeks, or months, based on the clinical course of the individual.

**Reference**

### AB-4: Flank Pain, Rule Out or Known Renal/Ureteral Stone

<table>
<thead>
<tr>
<th>Section Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>AB-4.1: Suspected Renal Stone</td>
<td>23</td>
</tr>
<tr>
<td>AB 4.2: Observation of Known Ureteral Stone</td>
<td>23</td>
</tr>
<tr>
<td>AB-4.3: Follow-Up of Treated Ureteral Stone</td>
<td>24</td>
</tr>
<tr>
<td>AB-4.4: Ultrasound</td>
<td>24</td>
</tr>
<tr>
<td>AB-4.5: This section intentionally left blank</td>
<td>25</td>
</tr>
</tbody>
</table>
AB-4.1: Suspected Renal Stone(s)

- Suspected renal stone with symptoms in non-pregnant adults (flank pain/renal colic).\(^1,2\)
  - CT Abdomen and Pelvis without contrast (CPT\textsuperscript® 74176)
- Suspected renal stone in pregnant women (flank pain/renal colic)\(^3,4\)
  - Ultrasound (CPT\textsuperscript® 76770 or CPT\textsuperscript® 76775) or MRI Abdomen and Pelvis without contrast (CPT\textsuperscript® 74181 and CPT\textsuperscript® 72195).
- Suspected renal Stone in Children (flank pain/renal colic)\(^4\)
  - Ultrasound (CPT\textsuperscript® 76770 or CPT\textsuperscript® 76775) or MR urogram (MRI Abdomen and Pelvis, without or with and without contrast [CPT\textsuperscript® 74181 or CPT\textsuperscript® 74183 and CPT\textsuperscript® 72195 or CPT\textsuperscript® 72197]) is the best initial study to avoid radiation exposure.
  - See PEDAB-4: Flank Pain, Renal Stone
- Suspicion Renal Stones (Flank pain/renal colic) with Hematuria
  - CT Abdomen and Pelvis without contrast (CPT\textsuperscript® 74176) or CT Urogram (CPT\textsuperscript® 74178)

AB-4.2: Observation of Known Ureteral Stone(s)

- Retroperitoneal ultrasound (CPT\textsuperscript® 76770 or CPT\textsuperscript® 76775) and KUB X-ray if the stone is radiopaque, individual is symptomatic, and/or has not passed the stone.
  - If the individual is asymptomatic and has passed the stone, follow-up imaging is not necessary.
  - If the individual has not passed the stone, but is asymptomatic and no stone or hydronephrosis is seen with the retroperitoneal US and KUB, follow-up imaging is not necessary.
- CT Abdomen and Pelvis without contrast (CPT\textsuperscript® 74176) if the stone is non-radiopaque, the individual is symptomatic, and/or has not passed the stone.
  - If the individual is not symptomatic and has passed the stone, follow up imaging is not necessary.
- Annual surveillance for stable individuals who have a history of stones may be indicated to assess for stone growth or formation of new stones:
  - Plain X-ray (KUB) should be performed for individuals with radiopaque stones.
  - Retroperitoneal ultrasound (CPT\textsuperscript® 76770 or CPT\textsuperscript® 76775) is the preferred modality for individuals with non-radiopaque stones.
**AB-4.3: Follow-Up of Treated Ureteral Stone(s)**

- **Post-shock wave lithotripsy (SWL):**
  - Retroperitoneal ultrasound (CPT® 76770 or CPT® 76775) is the appropriate initial follow-up imaging.
  - Retroperitoneal ultrasound (CPT® 76770 or CPT® 76775) and/or CT Abdomen and Pelvis (contrast as requested) may be indicated for:
    - Individuals who are symptomatic
    - Individuals with hydronephrosis
    - Individuals who have residual fragments
  - Individuals treated by SWL who have passed fragments, are asymptomatic and without hydronephrosis: No further imaging is required.

- **Post-medical expulsive therapy (MET):**
  - Individuals treated by MET who have passed a stone and are symptomatic should undergo retroperitoneal US.
    - CT Abdomen and Pelvis without and with contrast (CPT® 74178) if hydronephrosis is demonstrated with US
  - Individuals treated by MET who have passed a stone and are asymptomatic do not usually require follow-up imaging.

- **Post-ureteroscopic extraction with an intact stone:**
  - Retroperitoneal US for individuals without symptoms
  - CT Abdomen and Pelvis with contrast (CPT® 74177) for individuals with symptoms or hydronephrosis with US
  - Individuals without symptoms or hydronephrosis with US do not usually require follow-up imaging.

- **Post-ureteroscopic extraction requiring fragmentation of the stone(s):**
  - Retroperitoneal US for individuals without symptoms
    - CT Abdomen and Pelvis without contrast (CPT® 74176) for individuals without symptoms, but hydronephrosis with US.
    - Individuals without symptoms or hydronephrosis with US do not usually require follow-up imaging.
  - Retroperitoneal US and KUB for individuals with symptoms and a radiopaque stone.
  - CT Abdomen and Pelvis without contrast (CPT® 74176) for individuals with symptoms and a non-radiopaque stone.

- Retroperitoneal US and/or CT Abdomen and Pelvis without contrast with (contrast (CPT® 74177) as requested) may be indicated for individuals with persistent symptoms and/or hydronephrosis.

**AB-4.4: Ultrasound**

- Retroperitoneal ultrasound (CPT® 76770 or CPT® 76775) can be used in place of CT Abdomen and Pelvis at any of the initial or follow-up indications, if requested by Provider.
AB-4.5: This section intentionally left blank

References
AB-5: Gastroenteritis

AB-5.1: Gastroenteritis
AB-5.1: Gastroenteritis

CT Abdomen and Pelvis with contrast (CPT® 74177) if:

- Acute abdomen suggesting bowel obstruction, toxic megacolon (abdominal swelling, fever, tachycardia, elevated white blood cell count), or perforation
- Bloody stools
- Immunocompromised
- Previous gastric bypass
- Persistent abdominal pain and at least one of the following:
  - Failure of conservative treatment for 4 weeks
  - History of cancer
  - Fever (101 degrees or greater)
  - Mass
  - GI bleeding
  - Moderate to severe abdominal tenderness
  - Guarding, rebound tenderness, or other peritoneal signs
  - WBC 10,000 or greater
  - History of bariatric surgery

Background and Supporting Information

Gastroenteritis is a nonspecific term which denotes a constellation of symptoms including, to a varying degree, nausea, vomiting, diarrhea, and abdominal pain. It is usually caused by infectious agents such as norovirus. The broad differential of such symptoms evades establishing a guideline to evaluate gastroenteritis, as a specific entity, from an imaging standpoint.

References

# AB-6: Mesenteric/Colonic Ischemia

<table>
<thead>
<tr>
<th>AB-6.1: Mesenteric Ischemia</th>
<th>29</th>
</tr>
</thead>
<tbody>
<tr>
<td>AB-6.2: Colonic ischemia (including ischemic colitis)</td>
<td>29</td>
</tr>
</tbody>
</table>
AB-6.1: Mesenteric Ischemia

- Suspicion of acute mesenteric ischemia ONE of the following:
  - CTA Abdomen and/or Pelvis (Mesenteric) (CPT® 74174 or CPT® 74175 or CPT® 72191) (preferable), or
  - MRA Abdomen and/or Pelvis (CPT® 72198 and/or CPT® 74185), or
  - CT Abdomen and Pelvis with contrast (CPT® 74177).

- Routine post-procedure imaging following invasive treatment for mesenteric ischemia (bowel resection, embolectomy, etc.) is not needed in asymptomatic individuals.

Background and Supporting Information

- Typical presentation of mesenteric ischemia is based on severe abdominal pain out of proportion to findings on physical exam, usually in individuals with underlying risk factors including cardiovascular disease, atrial fibrillation, hypertension, etc.: AB-6.2: Colonic ischemia (including ischemic colitis)

- CT Abdomen and Pelvis with contrast (CPT® 74177) is considered the first imaging modality in order to assess the distribution and phase of the colitis, and it can be performed if abdominal pain and:
  - Lower GI bleed; or
  - Moderate or severe tenderness; or
  - Fever (101 degrees or greater); or
  - Guarding, rebound tenderness, or other peritoneal signs; or
  - Elevated WBC as per the testing laboratory’s range

- Repeat imaging for asymptomatic or unchanged symptoms, including routine post-operative imaging, is not needed.

- CTA Abdomen (CPT 74175) or MRA Abdomen (CPT 74185) can be performed for suspicion of right sided or pancolonic ischemia (as suggested on the initial CT Abdomen and Pelvis or by history)

Background and Supporting Information

- Gastroenteritis is a nonspecific term that denotes a constellation of symptoms including, to a varying degree, nausea, vomiting, diarrhea, and abdominal pain. It is usually caused by infectious agents such as norovirus. The broad differential of such symptoms evades establishing a guideline to evaluate gastroenteritis, as a specific entity, from an imaging standpoint.

- Suspicion of colonic ischemia based on sudden cramping abdominal pain accompanied by urgency to defecate and passage of bright red blood, maroon blood, or bloody diarrhea, with risk factors including cardiovascular disease, diabetes mellitus, kidney disease, previous abdominal surgery, use of constipating medications, COPD, and atrial fibrillation.
References


AB-7: Post-Operative Pain Within 60 Days Following Abdominal Surgery – Abdominal Procedure

AB-7.1: Post-Op Pain within 60 Days
AB-7.1: Post-Op Pain within 60 Days

- CT Abdomen and/or Pelvis with contrast (CPT® 74177 or CPT® 74160 or CPT® 72193) for suspected postoperative/post procedure complications (For example: bowel obstruction, abscess or anastomotic leak).

- Beyond 60 days postoperatively, See **AB-2: Abdominal Pain**

References


# AB-8: Abdominal Lymphadenopathy

<table>
<thead>
<tr>
<th>AB-8.1: Abdominal Lymphadenopathy</th>
<th>34</th>
</tr>
</thead>
<tbody>
<tr>
<td>AB-8.2: Inguinal Lymphadenopathy</td>
<td>34</td>
</tr>
</tbody>
</table>
AB-8.1: Abdominal Lymphadenopathy

- History of malignancy
  - Refer to oncology guidelines specific for that known malignancy
  - Biopsy may be considered
- Clinical or lab findings suggesting a lymphoproliferative disorder:
  - Biopsy
  - PET/CT (CPT® 78815) can be considered if biopsy is negative or inconclusive,
  - PET/CT (CPT® 78815) can be considered if requested to find the most appropriate LN for biopsy in this scenario.
    Clinical note: Due to its relative lack of specificity as well as higher cost, PET is a less efficient alternative to biopsy.
- Clinical or laboratory findings suggesting benign etiology, and no history of malignancy:
  - CT Abdomen/Pelvis (CPT® 74177) for 3-month follow-up.
  - If no changes at 3 months, 2 additional follow-up scans (at 6 months and one year) can be approved.
  - If no changes by one year, the finding can be considered benign. No further imaging.
- If a follow-up CT demonstrates a concerning change, biopsy should be performed. If biopsy is inconclusive, PET/CT (CPT® 78815) can be approved

AB-8.2: Inguinal Lymphadenopathy

There is no evidence-based support for advanced imaging of clinically evidenced inguinal lymphadenopathy without biopsy.

- Prior history of malignancy See ONC-31: Metastatic Cancer, Carcinoma of Unknown Primary Site, and Other Types of Cancer

Background and Supporting Information

- Localized inguinal lymphadenopathy should prompt:
  - Search for adjacent extremity injury or infection;
  - 3 to 4 weeks of observation if clinical picture is benign;
  - Excisional biopsy of most abnormal lymph node if condition persists or malignancy suspected; No advanced imaging indicated.
- Generalized inguinal lymphadenopathy should prompt:
  - Diagnostic work-up, including serological tests, for systemic diseases and
  - Excisional or image-guided core needle biopsy
References


**AB-9.1: Bariatric Surgery**

- **Pre-operative Assessment:**
  - Abdominal US (CPT® 76700 or CPT® 76705) to assess the liver and gallbladder

- **Post-operative complications:**
  - CT Abdomen and Pelvis with contrast (CPT® 74177) or CT abdomen with contrast (CPT® 74160) for individuals who have had weight loss surgery and who present with suspected complications including:
    - Weight loss failure
    - Heartburn
    - Nausea or vomiting
    - Abdominal pain
    - Fever
    - Abdominal distension
    - Suspected hernia

- Note: Internal hernias in individuals who have had Roux-En-Y gastric bypasses may have intermittent and relatively mild abdominal symptoms which require immediate evaluation with CT imaging.

- See [AB-7: Post-Operative Pain Within 60 Days Following Abdominal Surgery – Abdominal Procedure](#)

**Background and Supporting Information**

- Bariatric procedures include gastric banding, gastric bypass, sleeve gastrectomy, and biliopancreatic diversion procedures.

- Though abdominal pain in post-operative bariatric individuals may be gallbladder-induced and an US would be helpful for this diagnosis, the complications of bariatric surgery can become quickly life-threatening, and so any request for CT imaging in the post-operative bariatric individual should not be delayed with recommendations for US, even if the examination does not indicate any “red flags”.

**References**


**AB-10.1: Blunt Abdominal Trauma**

- Abdominal and/or pelvic ultrasound (CPT® 76700 and/or CPT® 76856) can be approved for the evaluation of blunt abdominal trauma when requested.

- CT Abdomen and/or Pelvis with contrast (CPT® 74160, or CPT® 72193, or CPT® 74177):
  - High probability intra-abdominal injury
    - Abdominal pain or tenderness
    - Pelvic or femur fracture
    - Lower rib fracture
    - Costal margin tenderness or evidence of thoracic wall trauma
    - Diminished breath sounds
    - Vomiting
    - Pneumothorax
    - Hematocrit < 30%
    - Hematuria
    - Elevated AST
    - Non-examinable individual (intoxicated, less than fully conscious, Glasgow Coma Scale Score > 13, etc.)
  - Evidence of abdominal wall trauma or seat-belt sign
  - If ultrasound demonstrates any positive finding(s)

**References**


https://www.doh.wa.gov/Portals/1/Documents/Pubs/530168.pdf


## AB-11: Gaucher’s Disease and Hemochromatosis

<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>AB-11.1</td>
<td>Gaucher’s Disease</td>
<td>41</td>
</tr>
<tr>
<td>AB-11.2</td>
<td>Hereditary (Primary) Hemochromatosis (HH) and Other Iron Storage Diseases</td>
<td>41</td>
</tr>
</tbody>
</table>
AB-11.1: Gaucher’s Disease

- MRI abdomen without contrast (CPT® 74181) and MRI lower extremity without contrast (CPT® 73718) for:
  - Individuals not on enzyme therapy every 12 to 24 months
  - Individuals on enzyme therapy every 12 months:
    - For change in dose of medication, complication from medication specific for treatment of Gaucher’s disease or clinical complication, individuals with active bone disease may require more frequent monitoring than once a year.

See PEDPN-4: Gaucher’s Disease in the Pediatric Guidelines

Background and Supporting Information

Gaucher’s disease is a lysosomal storage disease characterized by glucosylceramide accumulation in the spleen, liver, kidneys, lung, brain, and bone marrow

AB-11.2: Hereditary (Primary) Hemochromatosis (HH) and Other Iron Storage Diseases

- Elevated serum ferritin and transferrin saturation >45%
  - Positive HFE genetic testing (C282Y homozygote or C282Y/H63D or C282Y/S65C heterozygotes):
    - Transient elastography (CPT® 91200) or MRI abdomen without contrast (CPT® 74181) for iron quantification if:
      - Elevated AST or ALT or
      - Serum ferritin >1000
  - Negative HFE genetic testing
    - MRI abdomen without contrast (CPT® 74181) for iron quantification

- Elevated serum ferritin (males >300ng/mL, females >200ng/mL) and transferrin saturation <45%
  - MRI abdomen without contrast (CPT® 74181) for iron quantification

- For the evaluation of suspected hepatic iron overload in chronic transfusional states (e.g., sickle cell disease, thalassemia, oncology individuals, bone marrow failure, and stem cell transplant individuals):
  - MRI abdomen without contrast (CPT® 74181) for iron quantification can be performed annually

See PEDAB-18.2: Transfusion-Associated (Secondary) Hemochromatosis in the Pediatric Abdomen Imaging guidelines regarding transfusion-associated hepatic iron deposition.

- If transient elastography, biopsy, or MR reveal advanced fibrosis or cirrhosis, then follow HCC screening guidelines (See AB-26.1: Chronic Liver Disease, Cirrhosis and Screening for HCC).
References


### AB-12: Hernias

| AB-12.1: Inguinal or Femoral Hernia | 44 |
| AB-12.2: Spigelian, Ventral, Umbilical, or Incisional Hernia | 44 |
| AB-12.3: Hiatal Hernia               | 45 |
| AB-12.4: Indeterminate Groin Pain   | 45 |
**AB-12.1: Inguinal or Femoral Hernia**

- Initial imaging for known or suspected primary or recurrent inguinal or femoral hernia.
  - Limited (CPT® 76857) or complete (CPT® 76856) pelvic ultrasound; and/or
  - Limited (CPT® 76705) or complete (CPT® 76700) abdominal ultrasound
- CT Pelvis with contrast (CPT® 72193) or without contrast (CPT® 72192) for suspected incarceration or strangulation of an inguinal or femoral hernia or if requested by a specialist or surgeon.
- Ultrasound (pelvic limited [CPT® 76857] or pelvic complete [CPT® 76856]) is the initial imaging study if:
  - Vague groin swelling with diagnostic uncertainty
  - Poor localization of swelling (as might be seen with a small hernia and prominent overlying fat)
  - Intermittent swelling not present on examination
  - Other groin complaints without swelling
- CT Pelvis (with contrast, CPT® 72193, or without contrast, CPT® 72192) if ultrasound is indeterminate, or if a complication such as incarceration or strangulation is suspected.
- MRI Pelvis without contrast (CPT® 72195) or with and without (CPT® 72197) if CT and US are indeterminate or non-diagnostic.
- For chronic post-surgical groin pain (after hernia repair):
  - Pelvic ultrasound (CPT® 76856 or CPT® 76857) or US-guided nerve block
  - CT Pelvis with contrast (CPT® 72193) or without contrast (CPT® 72192) or MRI Pelvis without contrast (CPT® 72195) can be approved if either of the above studies are indeterminate or non-diagnostic, to assess for non-neuropathic causes.

**Background and Supporting Information**

- In most cases, a clinical examination alone is sufficient for the diagnosis of an inguinal or femoral hernia, and the individual can proceed to surgery without additional imaging.

**AB-12.2: Spigelian, Ventral, Umbilical, or Incisional Hernia**

- Known or suspected primary or recurrent Spigelian hernia (anterior abdominal wall hernia through the semilunar line), ventral hernia, umbilical, or incisional hernia:
  - CT Abdomen without or with contrast (if above the umbilicus) (CPT® 74150 or CPT® 74160)
  - CT Pelvis without or with contrast (if below the umbilicus) (CPT® 72192 or CPT® 72193)
  - CT Abdomen and/or Pelvis without or with contrast (if above and below the umbilicus) (CPT® 74176 or CPT® 74177)
AB-12.3: Hiatal Hernia

- CT Chest and/or Abdomen with contrast (CPT® 71260 and/or CPT® 74160) to evaluate any of the following:
  - GI specialist or surgeon request for treatment/pre-operative planning.
  - Suspected complication of primary disease or surgery.

Background and Supporting Information

- Some complications might include suspicion of a gastric volvulus (torsion) within the chest cavity, vomiting, chest pain, and difficulty in swallowing

AB-12.4: Indeterminate Groin Pain

- See MS-23: Pelvis in the Musculoskeletal Guidelines

References


### AB-13: Abdominal Mass

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>AB-13.1</td>
<td>Abdominal Wall Mass</td>
<td>47</td>
</tr>
<tr>
<td>AB-13.2</td>
<td>Intra-Abdominal Mass</td>
<td>47</td>
</tr>
</tbody>
</table>
AB-13.1: Abdominal Wall Mass

- Ultrasound (CPT® 76700 or CPT® 76705) or CT Abdomen and/or Pelvis (if below the umbilicus) with contrast (CPT® 74160 or CPT® 72193 or CPT® 74177) or without contrast (CPT® 74150 or CPT® 72192 or CPT® 74176).
- MRI Abdomen without and with contrast (CPT® 74183) or MRI Abdomen without contrast (CPT® 74181) can be considered if ultrasound and/or CT are equivocal, or for preoperative planning.¹

AB-13.2: Intra-Abdominal Mass

- If the physical exam suggests a palpable mass or a mass is seen on prior imaging, imaging can include ONE of the following:
  - CT Abdomen and/or Pelvis (if mass palpated below the umbilicus) with contrast (CPT® 74160 or CPT® 72193 or CPT® 74177) or
  - CT Abdomen and/or Pelvis (if mass palpated below the umbilicus) without contrast (CPT® 74150 or CPT® 72192 or CPT® 74176) or
  - MRI Abdomen and/or Pelvis (if mass palpated below the umbilicus) without contrast (CPT® 74181 and/or CPT® 72195) or
  - MRI Abdomen and/or Pelvis (if mass palpated below the umbilicus) without and with contrast (CPT® 74183 and/or CPT® 72197)

- Pregnant individual:
  - Abdominal and/or Pelvic and/or Transvaginal ultrasound (CPT® 76700 and/or CPT® 76856 and/or CPT® 76830) is appropriate for initial imaging
  - Follow-up Imaging if ultrasound findings are indeterminate (See AB-2.1: General Information)

- Abdominal and/or Pelvic ultrasound (CPT® 76700 and/or CPT® 76856) is appropriate for subcutaneous mass.

References

AB-14: Lower Extremity Edema

See PVD-7.5: Lower Extremity, Deep Venous Thrombosis (DVT) and/or Lower Extremity Edema in the Peripheral Vascular Disease Imaging Guidelines.
AB-15.1: Zollinger-Ellison Syndrome (ZES)

CT Abdomen with contrast (CPT® 74160) or MRI Abdomen without and with contrast (CPT® 74183) for known ZES

Background and Supporting Information

Zollinger-Ellison Syndrome is a complex condition in which one or more tumors form in the pancreas or upper part of the small intestine (duodenum).

Imaging is sometimes combined with Somatostatin Receptor Scintigraphy in the evaluation of suspected gastrinoma (elevated serum gastrin (normal value is < 100 pg/ml) and/or abnormal gastric acid secretory test).\(^1,2,3\)

References

## AB-16: Adrenal Cortical Lesions

<table>
<thead>
<tr>
<th>Section</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>AB-16.1</td>
<td>Adrenal Cortical Lesions</td>
<td>52</td>
</tr>
<tr>
<td>AB-16.2</td>
<td>This section intentionally left blank</td>
<td>55</td>
</tr>
<tr>
<td>AB-16.3</td>
<td>Adrenal Insufficiency</td>
<td>55</td>
</tr>
<tr>
<td>AB-16.4</td>
<td>This section intentionally left blank</td>
<td>56</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CPT®</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>74150</td>
<td>CT Abdomen without contrast</td>
</tr>
<tr>
<td>74160</td>
<td>CT Abdomen with contrast</td>
</tr>
<tr>
<td>74170</td>
<td>CT Abdomen without and with contrast</td>
</tr>
<tr>
<td>74181</td>
<td>MRI Abdomen without contrast</td>
</tr>
<tr>
<td>74183</td>
<td>MRI Abdomen without &amp; with contrast</td>
</tr>
<tr>
<td>78812</td>
<td>PET, Skull Base to Mid-Thigh</td>
</tr>
<tr>
<td>78815</td>
<td>PET/CT, Skull Base to Mid-Thigh</td>
</tr>
</tbody>
</table>
## AB-16.1: Adrenal Cortical Lesions

CT abdomen without contrast (CPT® 74150) is the initial imaging study for adrenal masses incidentally detected on ultrasound.

### Imaging Decision Tree: Incidentally Discovered Adrenal Mass

<table>
<thead>
<tr>
<th>Mass Details</th>
<th>Primary Study</th>
<th>Additional Studies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Incidental adrenal mass &lt;1 cm in short axis</td>
<td></td>
<td>Need not be pursued with further imaging, as it is uncertain as to whether subcentimeter nodularity or adrenal thickening qualifies as an adrenal mass on radiology reports.</td>
</tr>
</tbody>
</table>
| Asymptomatic adrenal mass ≥ 1 cm | Incidentally detected on any CT or MRI exam | No further imaging, regardless of size, if imaging is diagnostic for benign findings, including any of the following:  
  - Myelolipoma (macroscopic fat) or  
  - Calcified mass or  
  - < 10 HU on CT or decreased signal on Chemical Shift MRI (CS-MRI, CPT® 74181) consistent with benign adenoma, or  
  - If imaging was completed with and without contrast and no enhancement (defined as < 10 HU change between unenhanced and enhanced/contrasted CT scan e.g. cyst, hemorrhage)* |
| 1 to < 4 cm | Indeterminate imaging on any CT or MRI | 1 to 2 cm:  
  - 12 month CT Abdomen without and with contrast (adrenal protocol), or may consider CS-MRI (chemical shift MRI, CPT® 74181), especially if CT contraindicated  
    - If stable ≥ 1 year, no further imaging-likely benign  
    - If enlarging (or new lesion present):  
      - biochemical evaluation;  
      - consider resection for possible primary adrenocortical carcinoma;  
      - exclude pheochromocytoma prior to resection.  
  - > 2 cm to < 4 cm:  
    - CT Abdomen without and with contrast (adrenal protocol); may consider CS-MRI (chemical shift MRI, CPT® 74181), especially if CT contraindicated  
    - No further follow up imaging if:  
      - Absolute Percentage Washout/Relative Percentage Washout (APW/RPW) ≥ 60/40%: Benign adenoma;  
      - No enhancement (defined as change in pre- and post-contrast imaging of <10 HU Cyst or hemorrhage) |
<table>
<thead>
<tr>
<th>≥ 4 cm</th>
<th>No history of cancer</th>
<th>&gt; 10 HU on NCCT</th>
<th>Indeterminate imaging features on any CT or MRI</th>
<th>Biochemical assays to determine functional status to exclude pheochromocytoma prior to resection</th>
<th>Consider resection for possible primary adrenocortical carcinoma</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 cm to &lt; 4 cm</td>
<td>History of cancer</td>
<td>No prior imaging for comparison</td>
<td>Indeterminate imaging on any CT or MRI</td>
<td>CT abdomen without and with contrast (adrenal protocol); or</td>
<td>May consider CS-MRI (chemical shift MRI, CPT® 74181), especially if CT contraindicated</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>No further follow up imaging if:</td>
<td>APW/RPW &gt; 60/40%; Benign adenoma; or</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>No enhancement (defined as change in pre- and post-contrast imaging of &lt;10 HU e.g. cyst or hemorrhage);</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>APW/RPW &lt; 60/40%:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>PET CT; consider biopsy;</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Biochemical evaluation to determine functional status and exclude pheochromocytoma prior to biopsy/resection.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>If enlarging or new lesion:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>PET CT or biopsy;</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Biochemical evaluation to determine functional status and exclude pheochromocytoma prior to biopsy/resection</td>
</tr>
<tr>
<td>&gt; 4 cm</td>
<td>History of cancer</td>
<td>&gt; 10 HU on NCCT</td>
<td>Indeterminate imaging features on any CT or MRI</td>
<td>PET CT or biopsy</td>
<td>Consider biochemical assays to determine functional status and exclude pheochromocytoma prior to biopsy/resection</td>
</tr>
</tbody>
</table>

If APR/RPW <60/40%:
- Consider 6-12 month follow up imaging, or
- Resection for possible primary adrenocortical carcinoma, with biochemical evaluation to determine functional status and to exclude pheochromocytoma prior to resection.

If not resected, follow-up CT abdomen with and without contrast (or CS-MRI, CPT® 74181) in 6 – 12 months. May consider CS-MRI (chemical shift MRI, CPT® 74181), especially if CT contraindicated.
- If enlarging on follow up imaging: Consider resection for possible primary adrenocortical carcinoma; biochemical evaluation to determine functional status and to exclude pheochromocytoma prior to resection.

If not resected, follow-up CT abdomen with and without contrast (or CS-MRI, CPT® 74181) in 6 – 12 months. May consider CS-MRI (chemical shift MRI, CPT® 74181), especially if CT contraindicated.
<table>
<thead>
<tr>
<th>Suspected Condition</th>
<th>Initial Imaging</th>
<th>Additional Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Suspected Cushing’s Syndrome, or virilizing adrenal tumors</td>
<td>CT Abdomen without contrast*</td>
<td><strong>Laboratory</strong>: dexamethasone suppression, serum ACTH level, virilizing hormone levels, salivary cortisol, and/or 24 hour urine for adrenal hormones confirm adrenal cortical endocrine syndrome</td>
</tr>
<tr>
<td>Suspected Pheochromocytoma</td>
<td>MRI Abdomen or CT Abdomen (contrast as requested)</td>
<td>Chemical shift MRI (CPT® 74181) is the preferred imaging</td>
</tr>
</tbody>
</table>
| Conn’s Syndrome (hyperaldosteronism)                    | CT abdomen without contrast          | If PAC (plasma aldosterone concentration) > 20ng/dl plus undetectable PRA (plasma renin activity), plus spontaneously low potassium level (e.g. not diuretic-induced): proceed with advanced imaging.  
If PAC 15-19ng/dl plus low PRA plus PAC/PRA ratio > 20: Confirmatory testing demonstrating lack of aldosterone suppression needed prior to advanced imaging (See Practice Note).  
If adrenal vein sampling (AVS) is planned once primary aldosteronism is confirmed on biochemical and/or suppression testing: CT abdomen with contrast is indicated. |

**Background and Supporting Information**

- Above imaging can be applied to individuals with bilateral adrenal masses, with each lesion addressed separately.
- Benign calcified mass, such as and old hematoma or calcification from prior granulomatous infection needs no further imaging.
- Both benign and malignant adrenal masses may enlarge over time; there is not a known growth-rate threshold to differentiate benign from malignant adrenal masses.
- *If an adrenal mass does not demonstrate enhancement (defined as < 10 HU change between unenhanced and enhanced/contrasted CT scan), mass represents a cyst or hemorrhage and no further imaging is needed. Conversely, when an adrenal mass shows avid enhancement (>110 – 120 HU), a pheochromocytoma should be considered and biochemical evaluation with serum catecholamines is recommended.
- The most commonly used Confirmatory Aldosterone Suppression tests include: Sodium loading testing (oral or IV), Fludrocortisone Suppression Test (FST) and Captopril Challenge Test.
- The laboratory’s reference range performing renin (PRA) and serum potassium levels should be used for determining abnormalities of these levels.
AB-16.2: This section intentionally left blank

AB-16.3: Adrenal Insufficiency

- CT Abdomen without contrast (CPT® 74150) or MRI Abdomen without contrast (CPT® 74181) to determine the cause of primary adrenal insufficiency. Imaging is necessary if testing has confirmed adrenal insufficiency or adrenomyeloneuropathy.6,7

**Background and Supporting Information**

- The majority of “incidentalomas” are benign adenomas. The risk of primary adrenal carcinoma is as high as 5%. Metastases with history of malignancy are 25-75%. Routine screening for endocrine function is recommended since 5%-23% will be hormone secreting.

- Resection or biopsy is often considered for mass lesions larger than 4 cm or hormone-secreting tumors.*

- Biopsy is often considered if pheochromocytoma is excluded.

- Signs and symptoms of pheochromocytoma:
  - Flushing spells and/or poorly controlled hypertension.
  - Elevated plasma or urine metanephrines support the diagnosis of pheochromocytoma with sensitivity for diagnosis at 99.7%
  - If plasma metanephrines are not elevated, a 24-hour urine for catecholamine and metanephrine levels should be obtained prior to considering advanced imaging.
  - If catecholamine and metanephrine levels are not elevated in a 24-hour urine test, then no advanced imaging is indicated unless unexplained symptoms suggestive of pheochromocytoma persist.
  - Endocrine guidelines recommend biochemical evaluation in all incidental adrenal lesions with the exception of myelolipomas and cysts.

**Adenoma imaging characteristics:**

<table>
<thead>
<tr>
<th></th>
<th>Findings consistent with Adenoma</th>
<th>Indeterminate for Adenoma</th>
</tr>
</thead>
<tbody>
<tr>
<td>CT Abdomen without contrast</td>
<td>≤ 10 Hounsfield Units</td>
<td>&gt; 10 Hounsfield Units</td>
</tr>
<tr>
<td>CT with contrast with washout (calculated)</td>
<td>&gt; 60% absolute washout or &gt; 40% relative washout</td>
<td>&lt; 60% absolute washout or &lt; 40% relative washout</td>
</tr>
<tr>
<td>Chemical Shift MRI</td>
<td>Signal drop out</td>
<td>Lack of signal drop out</td>
</tr>
</tbody>
</table>

*Size > 4 cm or growth of a lesion are concerning for malignancy (though occasionally adenomas can demonstrate very slight growth on 6 to 12 month follow up imaging).
AB-16.4: This section intentionally left blank

References


# AB-17: Abdominal Aortic Aneurysm (AAA), Iliac Artery Aneurysm (IAA), and Visceral Artery Aneurysms Follow-Up of Known Aneurysms and Pre-Op Evaluation

| AB-17.1: Abdominal Aortic Aneurysm (AAA) | 59 |
| AB-17.2: Iliac Artery Aneurysm (IAA)    | 59 |
| AB-17.3: Visceral Artery Aneurysm       | 59 |
AB-17.1: Abdominal Aortic Aneurysm (AAA)

- See PVD-6: Aortic Disorders, Renal Vascular Disorders, and Visceral Artery Aneurysms in the Peripheral Vascular Disease Imaging Guidelines.

AB-17.2: Iliac Artery Aneurysm (IAA)

- See PVD-6: Aortic Disorders, Renal Vascular Disorders, and Visceral Artery Aneurysms in the Peripheral Vascular Disease Imaging Guidelines.

AB-17.3: Visceral Artery Aneurysm

- See PVD-6: Aortic Disorders, Renal Vascular Disorders, and Visceral Artery Aneurysms in the Peripheral Vascular Disease Imaging Guidelines.
AB-18.1: AAA, IAA, Post Endovascular or Open Aortic Repair

See PVD-6: Aortic Disorders, Renal Vascular Disorders, and Visceral Artery Aneurysms in the Peripheral Vascular Disease Imaging Guidelines.
<table>
<thead>
<tr>
<th>AB-19: Aortic Dissection and Imaging for Other Aortic Conditions</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>AB-19.1: Aortic Dissection and Other Aortic Conditions</td>
<td>63</td>
</tr>
<tr>
<td>AB-19.2: Imaging for Other Aortic Conditions</td>
<td>63</td>
</tr>
</tbody>
</table>
AB-19.1: Aortic Dissection and Other Aortic Conditions

See PVD-6: Aortic Disorders, Renal Vascular Disorders, and Visceral Artery Aneurysms in the Peripheral Vascular Disease Imaging Guidelines

AB-19.2: Imaging for Other Aortic Conditions

See PVD-6: Aortic Disorders, Renal Vascular Disorders, and Visceral Artery Aneurysms in the Peripheral Vascular Disease Imaging Guidelines
## AB-20: Bowel Obstruction and Gastroparesis

<table>
<thead>
<tr>
<th>AB-20.1: Bowel Obstruction</th>
<th>65</th>
</tr>
</thead>
<tbody>
<tr>
<td>AB-20.2: This section intentionally left blank</td>
<td>65</td>
</tr>
</tbody>
</table>
**AB-20.1: Bowel Obstruction**

- Plain X-rays abdomen as the initial study with suspected bowel obstruction.
- CT Abdomen and Pelvis with contrast (CPT® 74177) may be used for:
  - Plain X-rays that are abnormal or equivocal.
  - High index of suspicion for bowel obstruction (abdominal pain, vomiting, constipation, abdominal distention, failure to pass flatus), especially in individuals with prior history of abdominal surgery, history of malignancy, or individuals with current hernias. ¹

- For bariatric surgery individuals, See **AB-9.1: Bariatric Surgery**

**AB-20.2: This section intentionally left blank**

**References**

<table>
<thead>
<tr>
<th>AB-21: Diarrhea, Constipation, and Irritable Bowel</th>
</tr>
</thead>
<tbody>
<tr>
<td>AB-21.1: Acute and Persistent Diarrhea (up to 30 days)</td>
</tr>
<tr>
<td>AB-21.2: Chronic Diarrhea (more than 30 days)</td>
</tr>
<tr>
<td>AB-21.3: Constipation</td>
</tr>
<tr>
<td>AB-21.4: Bloating and/or Irritable Bowel Syndrome</td>
</tr>
</tbody>
</table>
AB-21.1: Acute and Persistent Diarrhea (up to 30 days)

- Routine advanced imaging is not supported for acute, or persistent (up to 30 days) uncomplicated, including infectious diarrhea.

- CT Abdomen and Pelvis with contrast (CPT® 74177) can be used if:
  - Suspected ischemia (See AB-6: Mesenteric/Colonic Ischemia)
  - Older (over 50) individuals with significant abdominal pain
  - Acute abdomen suggesting bowel obstruction, toxic megacolon (abdominal swelling, fever, tachycardia, elevated white blood cell count), or perforation
  - Bloody stools
  - Immunocompromised
  - Previous gastric bypass
  - Persistent abdominal pain and at least one of the following:
    - Failure of conservative treatment for 4 weeks
    - History of cancer
    - Fever (101 degrees or greater)
    - Mass
    - GI bleeding
    - Moderate to severe abdominal tenderness
    - Guarding, rebound tenderness, or peritoneal signs
    - WBC 10,000 or greater

Background and Supporting Information

- Travel and dysenteric (including bloody) diarrhea should undergo biological assessment and antimicrobial treatment.9,10,11 (See AB-2.1: General Information)

AB-21.2: Chronic Diarrhea (more than 30 days)

- CT Abdomen with contrast (CPT® 74160), CT Abdomen and Pelvis with contrast (CPT® 74177), CT Enterography (CPT® 74177), or MR Enterography (CPT® 74183 or CPT® 74183 and CPT® 72197), can be considered if both basic lab work and colonoscopy are negative.

- Basic lab work including routine CBC, chemistries, as well as stool tests for pathogens should be done prior to advanced imaging.
  - If diarrhea is watery – a secretory or osmotic etiology should be identified.
  - If diarrhea is bloody, it is inflammatory – requiring colonoscopy.
AB-21.3: Constipation

CT Abdomen and Pelvis with contrast (CPT® 74177) if:
- Acute abdomen suggesting bowel obstruction, toxic megacolon (abdominal swelling, fever, tachycardia, elevated white blood cell count), or perforation
- Bloody stools
- Immunocompromised
- Previous gastric bypass
- Persistent abdominal pain and at least one of the following:
  - Failure of conservative treatment for 4 weeks
  - History of cancer
  - Fever (101 degrees or greater)
  - Mass
  - GI bleeding
  - Moderate to severe abdominal tenderness
  - Guarding, rebound tenderness, or peritoneal signs
  - WBC 10,000 or greater
  - History of bariatric surgery
- MRI Defecography (MRI pelvis without contrast CPT® 72195) can be considered if the following conditions are met:
  - Individual has undergone ano-rectal manometry and a balloon-expulsion test, and the results confirm a defecatory disorder or are inconclusive and the individual has failed a trial of biofeedback or other conservative therapy.
  - Balloon expulsion test is normal and there is a need to identify structural lesions
  - To guide planned surgical therapy for rectoceles, cystoceles, or uterine prolapse.

Background and Supporting Information

The workup and treatment of constipation usually proceeds with a history and physical followed by empiric medication or dietary trials.
- In general, a colonoscopy is performed prior to advanced imaging in an individual presenting with chronic constipation if the alarm symptoms of blood in the stool, anemia, or weight loss are present.
**AB-21.4: Bloating and/or Irritable Bowel Syndrome**

- Colonoscopy should be performed prior to advanced imaging to rule out microscopic colitis or inflammatory bowel disease in individuals with IBS-D.

- Advanced imaging in the absence of alarm symptoms has a very low yield, but can be considered in the following circumstances (The ACG Task Force recommends against the routine use of abdominal imaging in individuals with IBS symptoms and no alarm features):
  - CT abdomen (CPT® 74160) or CT abdomen and pelvis (CPT® 74177) can be considered in the following circumstances:
    - Presence of alarm symptoms
      - Weight loss
      - Frequent nocturnal awakenings due to gastrointestinal symptoms
      - Fever
      - Blood in the stool (See **AB-22: GI Bleeding**)
      - New onset and progressive symptoms
      - Onset of symptoms after age 50
      - Recent antibiotic use
      - Family history of colon cancer or inflammatory bowel disease
      - Findings of an abdominal mass
      - Presence of lymphadenopathy
    - Positive findings on blood work including CBC (elevated WBC count), elevated CRP (a CRP < or = 0.5 essentially excludes inflammatory bowel disease in individuals with IBS symptoms), and celiac testing
    - Positive fecal calprotectin (Note: a fecal calprotectin level <40mcg/g virtually excludes inflammatory bowel disease in individuals with IBS) (See Practice Note in **AB-23.1: IBD Rule out Crohn’s Disease or Ulcerative Colitis**)

**Background and Supporting Information**

- Irritable bowel syndrome is characterized by abdominal pain associated with altered bowel habits, abdominal distention, and bloating. Subtypes include IBS-C (constipation-predominant), IBS-D (diarrhea-predominant) and IBS-M (mixed). Rome IV Criteria for the diagnosis of irritable bowel syndrome are:
  - Recurrent abdominal pain, on average ≥1 d/wk in the past 3 months, related to ≥ 2 of the following:
    - Defecation
    - Change in stool frequency
    - Change in stool appearance (form)
References


<table>
<thead>
<tr>
<th>AB-22.1: GI Bleeding</th>
<th>72</th>
</tr>
</thead>
<tbody>
<tr>
<td>AB-22.2: Small Bowel Bleeding Suspected</td>
<td>72</td>
</tr>
</tbody>
</table>
AB-22.1: GI Bleeding

- Endoscopy for upper GI bleeding as initial evaluation
- Colonoscopy for lower GI bleeding as initial evaluation
- CTA Abdomen (CPT® 74175) or CTA Abdomen and Pelvis (CPT® 74174) or CT Abdomen and Pelvis with contrast (CPT® 74177):
  - Active bleeding and if endoscopy is negative
  - If conventional angiography is being considered
  - If surgery is being considered
  - If colonoscopy cannot be performed in an individual with GI bleeding
    - CT Abdomen/Pelvis (CPT® 74177) with contrast can performed instead of CTA
  - GI bleeding and severe abdominal pain
  - GI bleeding and hemodynamic instability (shock)
  - If there is concern for an aorto-enteric fistula (known or suspected aortic aneurysm, history of any type of aortic aneurysm repair).
- Meckel’s scan (CPT® 78290) can be approved if bleeding is suspected from a Meckel’s diverticulum
- Gastrointestinal Bleeding Scintigraphy (CPT® 78278) can be considered if there is brisk active bleeding with negative endoscopy
- For TIPS placement, See AB-26.3: Portal Hypertension

AB-22.2: Small Bowel Bleeding Suspected

- If small bowel bleeding is suspected as the source of bleeding, and if upper and lower endoscopies are negative:
  - Video capsule endoscopy (VCE) is performed prior to advanced imaging.
  - VCE is not required prior to advanced imaging if small bowel obstruction or stricture is suspected.
  - CT Enterography (CPT® 74177) if upper and lower endoscopy are negative and if VCE is negative. If there is a contraindication to CTE, MRE (CPT® 74183 or CPT® 74183 and CPT® 72197) may be performed.
- Iron Deficient Anemia
  - If the bleeding is determined to be non-gastrointestinal (e.g. hematuria or vaginal bleeding), refer to the appropriate guideline for these conditions.
  - If the source is determined to be gastrointestinal:
    - Upper endoscopy and colonoscopy should be performed, unless contraindicated.
    - Small bowel video capsule endoscopy is next, if endoscopies are negative (unless contraindicated).
    - CT Abdomen and Pelvis with contrast (CPT® 74177), CT Enterography (CPT® 74177), or MR Enterography (CPT® 74183 or CPT® 74183 and CPT® 72197) (if CT Enterography is contraindicated) can be performed, if small bowel video capsule endoscopy is negative, or for further evaluation of abnormal video
Abdominal imaging findings. CT enterography should be considered the test of choice given the lack of motion artifact and its superior spatial resolution.

References


# AB-23: Inflammatory Bowel Disease

## Rule Out Crohn’s Disease or Ulcerative Colitis

<table>
<thead>
<tr>
<th>Section</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>AB-23.1</td>
<td>IBD Rule Out Crohn’s Disease or Ulcerative Colitis</td>
<td>75</td>
</tr>
<tr>
<td>AB-23.2</td>
<td>Known IBD</td>
<td>75</td>
</tr>
<tr>
<td>AB-23.3</td>
<td>Rectal Disease</td>
<td>76</td>
</tr>
<tr>
<td>AB-23.4</td>
<td>Primary Sclerosing Cholangitis (PSC)</td>
<td>76</td>
</tr>
<tr>
<td>AB-23.5</td>
<td>Special Considerations</td>
<td>76</td>
</tr>
</tbody>
</table>
**AB-23.1: IBD Rule out Crohn’s Disease or Ulcerative Colitis**

- **Suspected Crohn’s Disease or Ulcerative Colitis**
  - Chronic diarrhea without “Red Flags” (See AB-2.1: General Information and AB-21: Diarrhea, Constipation, and Irritable Bowel)
  - CT Abdomen and Pelvis with contrast (CPT® 74177) or CT Enterography (CPT® 74177) or MR Enterography (CPT® 74183 and CPT® 72197) if ANY of the following:
    - Acute abdomen suggesting bowel obstruction, toxic megacolon (abdominal swelling, fever, tachycardia, elevated white blood cell count), or perforation
    - Bloody stools
    - Immunocompromised
    - Previous gastric bypass
    - Persistent abdominal pain and at least one of the following:
      - Failure of conservative treatment for 4 weeks
      - History of cancer
      - Fever (101 degrees or greater)
      - Mass
      - GI bleeding
      - Moderate to severe abdominal tenderness
      - Guarding, rebound tenderness, or other peritoneal signs
      - WBC 10,000 or greater
      - History of bariatric surgery
  - CTE (CPT® 74177) or MRE (CPT® 74183 or CPT® 74183 and CPT® 72197) can be approved if no red flag is present and request is for the evaluation of chronic abdominal pain associated with diarrhea due to a concern for inflammatory bowel disease if:
    - There is a positive family history of inflammatory bowel disease, or
    - There are endoscopy or colonoscopy findings suggestive of inflammatory bowel disease, or
    - There is a CRP > or = 0.5 mg/dl, or a fecal calprotectin > 40 mcg/g. (See Practice Note)

**Background and Supporting Information**

Studies have demonstrated the negative predictive value of a low fecal calprotectin and CRP with regards to inflammatory bowel disease. Chey, et. al. in a meta-analysis demonstrated that a fecal calprotectin < 40mcg/g or a CRP < or = 0.5 mg/dl effectively excludes inflammatory bowel disease in individuals with IBS. Katsinelos, et. a. reviewed wireless capsule endoscopy results in individuals with abdominal pain and diarrhea, The diagnostic yield of capsule endoscopy in individuals with abdominal pain and diarrhea with positive inflammatory markers was 90.1%, and 0% in individuals with abdominal pain and diarrhea with negative inflammatory markers. This led the Canadian Association of Gastroenterology to recommend against the use of capsule endoscopy in persons with chronic abdominal pain or diarrhea as their only symptoms and no evidence of biomarkers associated with Crohn’s Disease, stating “CE (capsule endoscopy) is not warranted in most individuals who present with chronic abdominal...
pain in the absence of positive tests for inflammatory markers or abnormal findings on endoscopy or imaging

**AB-23.2: Known IBD**

- Known Crohn’s Disease or Ulcerative Colitis with suspected complications including abscess, perforation, fistula or obstruction, or monitoring response to therapy:
  - CT Abdomen/Pelvis (CPT® 74177), CT Enterography (CPT® 74177), or MR Enterography (CPT® 74183 or CPT® 74183 and CPT® 72197)
  - MRI Enterography is the test of choice for the follow up of young individuals with IBD given the lack of ionizing radiation and the need for lifetime follow up in many individuals.

**AB-23.3: Rectal Disease**

- Rectal/Peri-Rectal evaluation for fistula.
  - Endoscopic ultrasound, rectal ultrasound (CPT® 76872), MRI Pelvis without and with contrast (CPT® 72197), or CT Pelvis with contrast (CPT® 72193).

**AB-23.4: Primary Sclerosing Cholangitis (PSC)**

- Primary Sclerosing Cholangitis
  - MRCP should be considered after an ultrasound excludes biliary obstruction in those:
    - With IBD and elevated liver enzymes (any above normal).
    - Without IBD persistent cholestatic liver tests.
  - US or MRI/MRCP can be done as surveillance for cholangiocarcinoma in individuals with PSC every 6 months.

*Background and Supporting Information*

Primary sclerosing cholangitis (PSC) is a chronic liver and biliary tract disease that can result in stricturing and fibrosis of the intra- and extra-hepatic biliary ducts, as well as end-stage liver disease. It is most often associated with inflammatory bowel disease. Biliary obstruction can occur anywhere along the biliary tree, resulting in cholangitis, and there is a high risk of the development of cholangiocarcinoma, which must be strongly considered in individuals with PSC and a dominant stricture, as well as an increased risk of gallbladder polyps and other malignancies. As such, imaging plays an important role in the diagnosis and follow-up of PSC.

**AB-23.5: Special Considerations**

- CT Abdomen and Pelvis either with or without contrast (CPT® 74177 or CPT® 74176) prior to endoscopy if requested by the physician who will be performing the endoscopy, especially if there is suspected inflammatory bowel disease.
References


AB-24.1: Celiac Disease

- Endoscopy and biopsy of the small bowel is performed to confirm the diagnosis if the anti-tTG and EMA tests are positive.

- CT Abdomen and Pelvis with contrast (CPT® 74177) or CT Enteroclysis (CPT® 74176 or CPT® 74177) is appropriate for:
  - One time study after initial, confirmed diagnosis of Celiac Disease.
  - Confirmed Celiac disease and despite adherence to a gluten free diet the individual is experiencing new or continued weight loss, diarrhea, abdominal distention, or anemia.

- Diagnosis is made by blood testing¹:
  - Anti-tissue transglutaminase antibody (anti-tTG), anti-endomysium antibody (EMA), total IgA count, CBS to detect anemia, iron studies, ESR, C-reactive protein, complete metabolic panel, vitamin D, vitamin E, vitamin B12 levels

Background and Supporting Information

- Celiac is an autoimmune disease in which the villi of the small intestine are damaged from eating gluten (found in wheat, barley, and rye).

Reference

AB-25.1: CTC

Screening CTC (CPT® 74263) for colorectal cancer is NOT indicated if:
- FIT-DNA [multi-targeted stool DNA test, i.e., Cologuard] within the last 3 years, OR
- Colonoscopy within the last 10 years

Screening CTC (CPT® 74263) for colorectal cancer is NOT* indicated if:
- Individual with hereditary syndromes such as hereditary nonpolyposis colorectal cancer (HNPCC), OR
- Personal history of ulcerative colitis or Crohn colitis
- *The individual should be screened via colonoscopy

Screening CTC (CPT® 74263) for colorectal cancer can be performed as follows:
- Every 5 years in average-risk non-African American individuals ages 50 to 75 (average risk is defined as no previously diagnosed colorectal cancer, colonic adenomas, or inflammatory bowel disease involving the colon)
- Every 5 years in African-Americans beginning at age 45
- One-time screening CTC can be performed in individuals between age 76 to 85 if there is no history of a previously negative colonoscopy or CTC
- Individual with a SINGLE first-degree relative diagnosed at age > 60 years with colorectal cancer or an advanced adenoma can be screened every 5 years with CTC beginning at age 40. (If there are 2 or more first degree relatives at any age with CRC or an advanced adenoma, or a first degree relative < 60, the individual should be screened via colonoscopy, not CTC).

Diagnostic CTC (CPT® 74261, without contrast or CPT® 74262, with contrast, including non-contrast images if performed) can be used in:
- Failed conventional colonoscopy (e.g. due to a known colonic lesion, structural abnormality, or technical difficulty), and/or
- Conventional colonoscopy is medically contraindicated. Contraindications may include:¹
  - Coagulopathy
  - Intolerance to sedation
  - Elderly greater than or equal to 80 years of age
  - Recent (within the last 60 days) myocardial infarction (MI)

References
AB-26: Cirrhosis and Liver Screening for Hepatocellular Carcinoma (HCC); Ascites and Portal Hypertension

AB-26.1: Cirrhosis and Liver Screening for HCC

AB-26.2: Ascites

AB-26.3: Portal Hypertension
**AB-26.1: Chronic Liver Disease, Cirrhosis and Screening for HCC**

- US (CPT® 76700 or CPT® 76705) every 6 months in the presence of chronic liver disease, regardless of etiology
  - If liver nodule identified:
    - Less than 1 cm
      - Repeat US in 3 months, then every 3 to 6 months.
      - If stable for 2 years, then return to US every 6 months screening.
    - Greater than or equal to 1 cm
      - Multiphase CT (either CPT® 74160 or CPT® 74170) or MRI (CPT® 74183) should be performed
      - Repeat CT or MRI if not characteristic of HCC, or consider biopsy.
      - If second advanced imaging is not diagnostic – then consider biopsy.

- Advanced imaging may be appropriate if the US is technically limited by such factors as obesity (BMI >35), intestinal gas, or chest wall deformity.
  - MRI abdomen (CPT® 74183) or Multiphase CT abdomen (either CPT® 74160 or CPT® 74170).

- For negative US with AFP > 20 AND a > 2X increase in AFP from the previous low point within the past year:
  - MRI abdomen (CPT® 74183) or CT abdomen (CPT® 74170) can be approved, and if negative for a hepatic lesion, follow-up imaging resumes with US, unless further increases in AFP are documented.

- Ultrasound with contrast (CEUS, CPT® 76978, CPT® 76979) is only considered when MRI or CT cannot be performed, and the clinical situation requires ultrasound contrast to further delineate the nature of the lesion. CEUS of the liver is otherwise considered investigational or experimental at this time.

**Background and Supporting Information**

When performed for liver lesion evaluation, a multiphase CT protocol may include non-contrast imaging as well as arterial, portal venous, and delayed-phase post-contrast imaging. However, these protocols do not always require non-contrast imaging which may not provide additional information in many scenarios. Therefore, a multiphase CT for liver lesion evaluation can be requested as CPT® 74160 (abdominal CT with contrast) or CPT® 74170 (abdominal CT without and with contrast).

The American Association for the Study of Liver Diseases (AASLD) revised its guidelines with respect to surveillance for HCC in individuals with cirrhosis in 2017. The recommended algorithm now includes either US alone or US with serum AFP every 6 months. It should be noted that “modification of this surveillance strategy based on the etiology of liver diseases or risk stratification models cannot be recommended at this time.”

While AFP can be used in conjunction with US, its significance is controversial, and it is unclear that the use of US and AFP, as opposed to US alone improves survival. No specific cut-off value for AFP is endorsed by the AASLD as an indication for more advanced imaging, which are based solely on US findings. However, many specialists
continue to use AFP as part of surveillance. In an effort to address this question, Cheng, et al\(^8\) performed a retrospective analysis of 1597 individuals to compare US alone with US and AFP. Their findings suggest that an AFP cut-off of 20 ng/ml accompanied with a >2X increase in the AFP level from its nadir (low point) within the previous year produced a significant increase in sensitivity (with a very small decrease in specificity). The sequential increase in AFP value is important, since absolute values in cirrhosis may vary depending on the degree of inflammation.

**AB-26.2: Ascites**
- Abdominal Ultrasound (CPT\(^®\) 76700 or CPT\(^®\) 76705) with diagnostic paracentesis required for all initial evaluations to determine the need for advanced imaging.

**AB-26.3: Portal Hypertension**
- For noninvasive abdominal imaging:
  - Abdominal US (CPT\(^®\) 76700 or CPT\(^®\) 76705) (Duplex Doppler US [CPT\(^®\) 93975] of the liver and upper abdomen) is required for all initial evaluations to assist in determining the cause (pre-hepatic [e.g. portal vein thrombosis, extrinsic compression from a tumor], intrahepatic [e.g. cirrhosis], and post-hepatic [e.g. hepatic vein thrombosis]).
- For inconclusive US or further evaluation of US findings:
  - Multiphase CT Abdomen (CPT\(^®\) 74160 or CPT\(^®\) 74170), multiphase CTA Abdomen (CPT\(^®\) 74175), multiphase MRA Abdomen (CPT\(^®\) 74185), or MRI Abdomen liver protocol (CPT\(^®\) 74183)
- TIPS (transjugular intrahepatic portosystemic shunt)
  - Pre-procedure evaluation:
    - Abdominal US, including Doppler (CPT\(^®\) 76700 and/or CPT\(^®\) 93975), Multiphase CT Abdomen (CPT\(^®\) 74160 or CPT\(^®\) 74170), multiphase CTA Abdomen (CPT\(^®\) 74175), multiphase MRA Abdomen (CPT\(^®\) 74185), or MRI Abdomen liver protocol (CPT\(^®\) 74183) See **AB-43.1: Hepatic Arteries and Veins**
  - For routine follow-up to monitor stent patency:
    - US with Doppler (CPT\(^®\) 93975) 7-14 days after shunt creation, and then at 3 months, 6 months, and then every 6 months thereafter
      - (Note: Doppler can be approved if requested earlier than the above intervals because of a clinical deterioration or suspicion of stent occlusion.)
    - If Doppler imaging is indeterminate or if there is a negative Doppler with clinical signs of worsening portal hypertension:
      - Multiphase CT Abdomen (CPT\(^®\) 74160 or CPT\(^®\) 74170), multiphase CTA Abdomen (CPT\(^®\) 74175), multiphase MRA Abdomen (CPT\(^®\) 74185), or MRI Abdomen liver protocol (CPT\(^®\) 74183)
- Certain requests are made for advanced imaging to evaluate an individual with cirrhosis for the presence of esophageal varices. In general, and in the absence of a
contraindication, endoscopy should be performed in individuals to assess for the presence of varices.

**Background and Supporting Information**

- Hepatic Venous Pressure Gradient (HPVG [pressure gradient between portal vein and the inferior vena cava]) is an invasive test and is the gold standard for the assessment for portal hypertension.

- Most cases of portal hypertension are caused by cirrhosis, and the most feared complication is that of esophageal variceal hemorrhage. Causes of portal hypertension can be divided into prehepatic (e.g. portal vein thrombosis, extrinsic compression from a tumor), intrahepatic (e.g. cirrhosis) and post-hepatic (e.g. hepatic vein thrombosis) causes. The differentiation of some of these causes may require workup which includes measurement of the hepatic venous pressure gradient (HVPG) which is considered the gold standard for the evaluation of portal hypertension.

**References**


AB-27: MR Cholangiopancreatography (MRCP)

AB-27.1: MRCP
AB-27: MR Cholangiopancreatography (MRCP) - General

MRCP is an alternative to endoscopic retrograde cholangiopancreatography (ERCP) for evaluating the biliary system and pancreatic ducts.

AB-27.1: MRCP

- Rule out pathology in the biliary system or pancreatic duct.
  - Examples include:
    - Suspected or known gallstone pancreatitis
    - Suspected biliary pain
    - Pancreatic pseudocyst (for preoperative cyst drainage and/or pancreatic trauma with suspected duct injury)
    - Pancreatic trauma
    - Recurrent acute pancreatitis with no known cause
- Preoperative planning
- Evaluation of congenital anomaly of pancreaticobiliary tract.
- Altered biliary anatomy that precludes ERCP (e.g. post-surgical distorted anatomy).
- Failed ERCP in an individual who needs further investigation.
- Evaluation of pancreaticobiliary anatomy proximal to a biliary obstruction that cannot be opened by ERCP.
- ERCP is indicated but is not available, is contraindicated, or is expected to be difficult.
  - Examples include: coagulopathy, severe cardiopulmonary disease, allergy to iodinated contrast, distorted anatomy, and pregnant individuals.
- Requests for 3D rendering do not need to be sent to MD for review when criteria are met for MRCP as indicated above.

References

## AB-28: Biliary Tract Disease Jaundice

| AB-28.1: Jaundice                | 90 |
| AB 28.2: Gallbladder Polyps     | 90 |

---
AB-28.1: Jaundice

- Ultrasound\(^1\) (CPT\(^\circledR\) 76700 or CPT\(^\circledR\) 76705) to visualize the biliary ductal system when pain is present.

- Abdomen CT\(^2\) without and with contrast (CPT\(^\circledR\) 74170) or Abdomen CT with contrast (CPT\(^\circledR\) 74160):
  - If non-diagnostic or equivocal ultrasound
    - e.g. large amounts of intestinal gas
  - Individual is obese (BMI >35).
  - Painless jaundice
  - Acute abdominal pain and one of the following: fever, previous biliary surgery, or known cholelithiasis.
  - If there is high pretest probability of obstruction due to malignancy.\(^1\)

- MR Cholangiopancreatography (MRCP) (See AB-27: MR Cholangiopancreatography (MRCP)) may be used to assess the extent and cause of intrahepatic bile duct obstruction when ANY of the following:
  - Suggested by either ultrasound or CT if further characterization is warranted.
  - Contraindications to the use of IV contrast for CT imaging.

AB 28.2: Gallbladder Polyps

- Incidentally identified polyps less than 6mm in size do not require further follow-up.\(^3,4\)

- Polyps 6 to 9 mm:
  - Ultrasound (CPT\(^\circledR\) 76700 or CPT\(^\circledR\) 76705) can be repeated in 6 months, and if no change in size or morphology, repeat US in another 12 months. If no changes, no additional imaging.

- Polyps of any size associated with primary sclerosing cholangitis:
  - Surgical consultation is appropriate
  - CT (CPT\(^\circledR\) 74170) may be approved for further characterization of the lesion and for surgical planning.

- Advanced imaging for the evaluation of gallbladder polyps can be considered in the following circumstances:
  - CT abdomen (CPT\(^\circledR\) 74160 or CPT\(^\circledR\) 74170) if:
    - Age > 60
    - Polyp noted to have a sessile morphology or is suspicious for malignancy in the radiology report.
    - Polyps > 10mm
  - Follow-up imaging with CT abdomen (CPT\(^\circledR\) 74160 or CPT\(^\circledR\) 74170) can be done at 6 months, and then at another 12 months.
References
<table>
<thead>
<tr>
<th>AB-29: Liver Lesion Characterization</th>
</tr>
</thead>
<tbody>
<tr>
<td>AB-29.1: Liver Lesion Characterization</td>
</tr>
</tbody>
</table>
**AB-29.1: Liver Lesion Characterization**

- No further diagnostic imaging is needed if:
  - Simple cyst
  - Fatty liver (steatosis) without findings suspicious for a focal liver lesion(s)\(^7,8\)

- Ultrasound\(^1\) (CPT® 76700 or CPT® 76705) should be considered:
  - For suspected hepatomegaly
  - For suspected simple cyst
  - For initial study if suspect liver lesion without history of malignancy

- Ultrasound with contrast (CEUS, CPT® 76978, CPT® 76979) is only considered when MRI or CT cannot be performed, and the clinical situation requires ultrasound contrast to further delineate the nature of the lesion. CEUS of the liver is otherwise considered investigational or experimental at this time

- See **AB-26: Cirrhosis and Liver Screening for Hepatocellular Carcinoma (HCC); Ascites and Portal Hypertension**

- Abdominal MRI or CT are the best studies to evaluate an indeterminate liver lesion (ACR 2014\(^11,12\))

<table>
<thead>
<tr>
<th>Liver Lesion</th>
<th>Initial Imaging</th>
<th>Repeat Imaging</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lesion with Chronic Liver Disease (see Cirrhosis)(^9)</td>
<td>See Cirrhosis (AB-26)</td>
<td>See Cirrhosis (AB-26)</td>
</tr>
<tr>
<td>Liver lesion with significant risk factors such as a history of malignancy, elevated tumor markers, or unintentional weight loss(^9)</td>
<td>Multiphase CT (CPT® 74160 or CPT® 74170) or Liver MRI (MRI Abdomen [CPT® 74183])</td>
<td>If indeterminate, follow-up CT or MRI every 6 months for 2 years, and then annually, to establish any growth patterns and assess for malignant transformation.</td>
</tr>
<tr>
<td>Incidental lesions on US or CT without a dedicated liver protocol(^9)</td>
<td>Multiphase CT (CPT® 74160 or CPT® 74170) or Liver MRI (MRI Abdomen [CPT® 74183])</td>
<td>If indeterminate, follow-up CT or MRI every 6 months for 2 years, and then annually, to establish any growth patterns and assess for malignant transformation.</td>
</tr>
<tr>
<td>Suspected Hepatic Adenoma(^9)</td>
<td>MRI Abdomen (CPT® 74183) is considered the best technique for characterization.</td>
<td>Follow-up CT or MRI every 6 months for 2 years, and then annually, to establish any growth patterns and assess for malignant transformation.</td>
</tr>
<tr>
<td>Hepatic Hemangioma (HH)(^9)</td>
<td>Multiphase CT (CPT® 74160 or CPT® 74170) or Liver MRI (MRI Abdomen [CPT® 74183]) are reliable in establishing the diagnosis.</td>
<td>Follow-up imaging is not required if the advanced imaging study demonstrates classic features of hemangioma. The exception is giant hemangiomas (&gt; 4 cm) in which follow up ultrasound can be done in 6 to 12 months, and if there is no change in size, no further follow up is indicated, unless it becomes symptomatic.</td>
</tr>
</tbody>
</table>
Liver Lesion | Initial Imaging | Repeat Imaging
--- | --- | ---
Focal Nodular Hyperplasia (FNH) | MRI (CPT® 74183) or Multiphase CT (CPT® 74160 or CPT® 74170) to confirm a diagnosis of FNH. The use of Eovist contrast is often diagnostic in differentiating FNH from other lesions seen on MRI or CT | FHN based on prior imaging characteristics or biopsy, and are not using oral contraceptives, do not require follow-up imaging. Follow-up annual US for 2 to 3 years is appropriate in women diagnosed with FNH who are continuing to use OCPs. Follow-up with CT (CPT® 74160 or CPT® 74170) or MRI (CPT® 74183) can be done if the lesion is not adequately visualized on US.

Hepatic cysts | US shows internal septations, fenestrations, calcifications, irregular walls, as well as the presence of daughter cysts should be evaluated with CT or MRI for features of biliary cystadenoma or a hydatid cyst. | Asymptomatic, simple cysts do not require additional follow-up.

Other indications for MRI Abdomen without and with contrast (CPT® 74183), CT Abdomen without and with contrast (CPT® 74170), or CT with contrast (CPT® 74160):
- Percutaneous liver biopsy is to be considered if imaging is atypical or inconclusive.⁴
- Diagnosis for HCC is done with imaging, biopsy is not needed for diagnosis. ⁵
- Suspected liver metastases; See ONC-31.2: Liver Metastases.
- Fatty liver on US with a focal liver lesion(s).⁷

Further evaluation
- MRI Abdomen without and with contrast (CPT® 74183) can be considered if an initially performed CT Abdomen without and with contrast (CPT® 74170) or CT with contrast (CPT® 74160) is equivocal.
- MRA Abdomen (CPT® 74185) or CTA Abdomen (CPT® 74175) for preoperative study in individuals with large hemangiomas or adenomas considered for resection.

Background and Supporting Information
- If fatty infiltration is demonstrated by US, neither CT nor MRI can distinguish between steatosis and steatohepatitis. Clinically, additional workup of fatty liver is biochemical, serologic, and may include a liver biopsy as potential etiologies are sought.⁷,⁸
References


AB-30: Elevated Liver Function (LFT) Levels

AB-30.1: Elevated Liver Function Levels
**AB-30.1: Elevated Liver Function Levels**

- A Doppler study can be approved for the evaluation of elevated liver tests if there is a suspicion or concern for veno-occlusive disease.

- For elevated ALT and/or AST above the upper limit of normal (ULN) per the lab where it was drawn and other LFTs are normal:
  - < 2X normal:
    - Repeat lab after 3 weeks and discontinuation of medications associated with elevated LFTs (such as statins, niacin, sulfa, rifampin, tetracycline, estrogen) if applicable.
    - Abdominal US (CPT® 76700 or CPT® 76705) if LFTs remain elevated.
  - 2 to 15X normal:
    - Abdominal US with Doppler (CPT® 76700 or CPT® 76705 and CPT® 93975).
  - > 15X normal:
    - Abdominal US with Doppler (CPT® 76700 or CPT® 76705 and CPT® 93975).

- Elevated alkaline phosphatase level, and other LFTs are normal:
  - Etiology of elevated ALKP should be determined prior to imaging.
    - If isolated ALKP elevation, GGT should be obtained for confirmation of hepatic etiology, prior to imaging. If ALKP is elevated with other LFTs, no confirmatory test is necessary.
    - RUQ ultrasound (CPT® 76705) for confirmed hepatic etiology of elevated ALKP,
      - MRCP if dilated biliary ducts on US.
    - If no dilated biliary ducts: anti-mitochondrial antibody (AMA) should be checked prior to advanced imaging.
      - MRCP if AMA is negative, and ALKP > 2X ULN
      - if AMA is negative, and ALKP 1 to 2X ULN: observe for 6 months, If ALKP remains elevated: MRCP.

- Isolated elevated bilirubin (no other LFTs elevated).
  - An isolated elevated bilirubin should be fractionated into direct (conjugated) and indirect (unconjugated) levels.
    - If elevation is unconjugated, and no other LFT elevations: No advanced imaging.
    - RUQ ultrasound if elevation is conjugated
      - MRCP if biliary ducts dilated.
      - If biliary ducts not dilated: check AMA prior to advanced imaging.
        - MRCP or liver biopsy can be considered if negative and elevation persists or is unexplained.

- For individuals with elevated LFTs and suspicion of sclerosing cholangitis, such as those with IBD, See **AB-23.4: Primary Sclerosing Cholangitis (PSC).**

- For individuals with elevated LFTs and history of underlying malignancy, please refer to the specific oncology guidelines, when appropriate.
- Requests for additional advanced imaging (CT, MRI, etc.) are based on the US or MRCP results, as appropriate to the finding (for example, if a lesion is identified that needs further characterization, refer to liver lesion imaging as per AB-29.1: Liver Lesion Characterization).

**Background and Supporting Information**

- The standard laboratory tests commonly referred to as “LFTs” include bilirubin, alkaline phosphatase (alk phos or ALKP), aspartate transaminase (AST), alanine transaminase (ALT), and gamma-glutamyl transferase (GGT). There are 4 major patterns of elevation which affect workup:
  - Hepatocellular (AST and ALT disproportionately elevated to ALKP.)
  - Cholestatic (ALKP elevated disproportionately to AST and ALT)
  - Mixed pattern (ALKP, AST, and ALT all elevated)
  - Isolated hyperbilirubinemia (elevated bilirubin and normal ALKP, ALT and AST)

**References**

<table>
<thead>
<tr>
<th><strong>AB-31: Pancreatic Lesion</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>AB-31.1: Pancreatic Cystic Lesions</strong></td>
</tr>
<tr>
<td><strong>AB-31.2: Incidental Pancreatic Mass or Suspected Metastatic Disease to Pancreas</strong></td>
</tr>
</tbody>
</table>
AB-31.1: Pancreatic Cystic Lesions
Screening studies for pancreatic cancer can be considered in those who are considered high risk in the following guideline: **ONC-13: Pancreatic Cancer** in the Oncology Imaging Guidelines.

- **Note:**
  - Individuals who are not medically fit for surgery should not undergo further surveillance of incidentally found pancreatic cysts, irrespective of size.
  - Surveillance should be discontinued if an individual is no longer a surgical candidate. However, follow-up imaging can be performed if requested for a symptomatic cyst (such as the development of jaundice secondary to cyst), in which palliative treatment might be available.

- This guideline applies to the following pancreatic cystic lesions:
  - Intraductal papillary mucinous neoplasms (IPMN)
  - Mucinous cystic neoplasms (MCN)
  - Serous Cystadenomas (SCA)
  - Solid-pseudopapillary neoplasms (SPN)

- **Pancreatic Cyst seen on Imaging-Initial Management:**
  - MRI Abdomen (CPT® 74183) and/or MRCP are the tests of choice for initial evaluation.
  - Pancreatic protocol CT (CPT® 74170) or EUS are alternatives in individuals who are unable to undergo MRI.
  - Indeterminate cysts may benefit from a second imaging modality or EUS prior to proceeding with surveillance. MRI/MRCP can be approved to better characterize the lesion, without reference to the timeframe for follow-up imaging, if a previous US or CT Abdomen has been performed.
  - Radiographic diagnosis of a non-neoplastic cyst or classic features of a serous cystadenoma
    - No further imaging
  - If any of the following are present the individual should proceed to EUS + FNA and depending on findings, surgical consultation:
    - Main duct >5mm
    - Cyst > 3cm
    - Change in main duct caliber with upstream atrophy
  - If EUS does not reveal findings of main duct involvement, patulous ampulla, cytology with high-grade dysplasia or pancreatic malignancy, or a mural nodule, then follow up MRI should performed in 6 months.

- **Pancreatic Cyst Follow up Imaging**
  - If high risk features are not present, then the next follow-up imaging proceeds as follows:
    - Cyst <1cm: MRI in 2 years
    - Cyst 1-2cm: MRI in 1 year
    - Cyst 2-3cm: if cyst is not clearly an IPMN or MCN then proceed with EUS. If it is an IPMN or MCN, then MRI at 6-12 months.
If the cyst is determined to be a serous cystadenoma, then no further evaluation unless symptomatic.

**Additional Surveillance for a presumed IPMN or MCN (imaging from time of presentation):**

(Note: MRCP or MRI/MRCP is the preferred modality for surveillance due to non-invasiveness, lack of radiation, and improved delineation of the main pancreatic duct)

- **Cyst <1cm**
  - MRI every 2 years for 4 years.
  - If stable after 4 years consider lengthening of interval imaging.
  - If increase in cyst size, then MRI or EUS in 6 months.
  - If stable, repeat again in 1 year and if stable return to MRI every 2 years.

- **Cyst 1-2cm**
  - MRI yearly for 3 years
  - If stable for 3 years, then change to MRI every 2 years for 4 years
  - If stable after the additional 4 years, consider lengthening of interval for surveillance.
  - If increase in cyst size, repeat MRI in 6 months. If stable, repeat MRI in 1 year and if remains stable, resume original surveillance schedule.

- **Cyst 2-3cm**
  - MRI every 6-12 months for 3 years
  - If stable after 3 years, change to MRI every year for 4 years
  - If remains stable, consider lengthening of surveillance interval

- **Cyst >3cm**
  - MRI alternating with EUS every 6 months for 3 years
  - If stable for 3 years, increase interval to MRI alternating with EUS yearly for 4 years.
  - If remains stable, consider lengthening of surveillance interval.
  - If increase in cyst size, EUS + FNA

**Additional considerations**

- Individuals with asymptomatic cysts that are diagnosed as pseudocysts on initial imaging and clinical history, or are determined to be serous cystadenomas, do not require further evaluation.

- Individuals with IPMNs or MCNs with new onset or worsening diabetes, or a rapid increase in cyst size (>3mm/year) during surveillance may have an increased risk of malignancy and should undergo a short-interval MRI or EUS. Additional features which may prompt early evaluation are:
  - Jaundice secondary to the cyst, acute pancreatitis secondary to the cyst, significantly elevated CA 19-9
  - The presence of a mural nodule or solid component either within the cyst or in the pancreatic parenchyma, dilation of the main pancreatic duct >5mm, a focal dilation of the pancreatic duct concerning for main duct IPMN or an obstructing lesion, IPMNs or MCNs measuring ≥3cm in diameter
The presence of high-grade dysplasia or pancreatic cancer on cytology. In these circumstances, imaging should be at the discretion of the provider.

Post-op surveillance
- Surgically resected serous cystadenomas, pseudocyst, or other benign cyst:
  - No additional imaging after resection
- Surgically resected mucinous cystic neoplasms (MCNs) without an associated pancreatic malignancy (can have low, intermediate, or high-grade dysplasia):
  - No additional post-op surveillance
- Surgically resected MCNs with invasive cancer:
  - Standard surveillance-based pancreatic cancer guidelines (See ONC-13.5: Surveillance/Follow Up) for 5 years. No surveillance required after 5 years.
- Surgically resected IPMNs
  - IPMN with cancer
    - Pancreatic cancer surveillance guidelines (See ONC-13.5: Surveillance/Follow Up)
  - IPMN with high-grade dysplasia
    - MRI abdomen (CPT® 74183) or EUS every 6 months
  - IPMN with low- or intermediate-grade dysplasia
    - MRI abdomen (CPT® 74183) every 2 years
- Surgically resected solid-pseudopapillary neoplasm with negative margins:
  - MRI abdomen (CPT® 74183) yearly for 5 years.

See AB-27: MR Cholangiopancreatography (MRCP) for coding guidelines for MRCP.

AB-31.2: Incidental Pancreatic Mass or Suspected Metastatic Disease to Pancreas
- CT Abdomen with contrast with dual phase imaging (CPT® 74160), or CT Abdomen without and with contrast (CPT® 74170) (dedicated pancreatic protocol) since the majority of pancreatic tumors will enhance following IV contrast).

References
AB-32.1: Pancreatic Pseudocysts

- CT Abdomen with contrast (CPT® 74160), or without and with contrast (CPT® 74170), or MRI Abdomen without and with contrast (CPT® 74183)
  - Minimal symptoms - every two weeks, up to six weeks total. Thereafter, every 4 weeks.
  - Anytime symptoms worsen, including development of ascites or pleural effusion, increasing serum amylase, or if drainage of the cyst is planned.

- MRCP for preoperative planning cyst drainage:
  - See AB-27: MR Cholangiopancreatography (MRCP) for coding guidelines for MRCP

- MRCP for pancreatic trauma with suspected duct injury or pseudocyst.

Background and Supporting Information
Endoscopic ultrasound has increasingly become an important imaging modality in evaluating pseudocysts.

Reference
**AB-33.1: Pancreatitis**

- Ultrasound\(^2\) (CPT\(^®\) 76700 or CPT\(^®\) 76705) is the first study to evaluate:
  - Mild and uncomplicated symptoms of epigastric pain described as uncomfortable without guarding to rule out gallstone disease.
  - If ultrasound suggests uncomplicated pancreatitis, then advanced imaging is not necessary. For complicated pancreatitis, see below.

- CT Abdomen\(^2\) with contrast (CPT\(^®\) 74160), without contrast (CPT\(^®\) 74150) or without and with contrast (CPT\(^®\) 74170).
  - Suspected complications including peripancreatic effusions, pseudocysts, abscess, and pancreatic necrosis.
  - Lipase and/or amylase greater than or equal to three times the upper limit of normal and *any one* of the following:
    - Fever (101 degrees or greater)
    - Elevated WBC as per the testing laboratory’s range
    - Mass
    - No improvement with medical therapy
  - If the initial presentation is atypical, with equivocal amylase or lipase, and if other etiologies for the abdominal pain, such as bowel perforation or ischemia are being considered.
  - Suspected pancreatitis and ultrasound findings do not explain symptoms (gallstones, common duct, etc.).
  - Plain abdominal X-ray (KUB) and ultrasound (CPT\(^®\) 76700 or CPT\(^®\) 76705) are not characteristic and diagnostic in known chronic pancreatitis.

- MRI Abdomen without and with contrast\(^2\) (CPT\(^®\) 74183) is considered if:
  - The clinical indications for CT are met or equivocal, but there are contraindications for its use.

- MR Cholangiopancreatography\(^1,2\)-can be considered if:
  - Suspected gallstone pancreatitis to screen for those individuals who would benefit from ERCP.
  - Recurrent, acute pancreatitis with no known cause.
  - Evaluation of individuals with suspicion of pancreatic ductal anomalies that may predispose them to pancreatitis.
  - Plain abdominal x-ray (KUB) and ultrasound (CPT\(^®\) 76700 or CPT\(^®\) 76705) are not characteristic and diagnostic in known chronic pancreatitis and the MRI findings will affect management decisions.
  - MRCP - See **AB-27: MR Cholangiopancreatography (MRCP)** for coding guidelines for MRCP
**Background and Supporting Information**

The diagnosis of acute pancreatitis is often made by fulfilling two of the following three (3) conditions:\(^1\):

1. Typical pain (acute onset of epigastric pain radiating to the back that is persistent without relief, frequently associated with nausea and vomiting, and associated with severe epigastric tenderness and/or guarding, and/or fever).
2. Lipase and/or amylase greater than or equal to three times the upper limit of normal.
3. Typical characteristics of pancreatitis on CT Abdomen.

Chronic pancreatitis that is **suspected** as evidenced by recurrent characteristic pancreatic pain, symptoms of maldigestion/malabsorption that improve with digestive enzymes, does not require the use of advanced imaging.\(^1\)

For known chronic pancreatitis including hereditary pancreatitis, there is no evidence-based data supporting screening.\(^1\)

Acute pancreatitis is divided clinically into non-severe (previously called mild) and severe pancreatitis.\(^3\)

- Non-severe pancreatitis represents interstitial edematous pancreatitis, and severe pancreatitis manifests as necrotizing pancreatitis or as pancreatitis associated with organ failure.
- Serum enzyme levels do not correlate with the severity of the disease
- Clinical scoring systems and imaging tests have been advocated to classify individuals in terms of severity.
- The diagnosis may be overlooked in the absence of typical enzyme elevation; in some individuals, acute pancreatitis may be present in the absence of enzyme abnormalities.

**References**

AB-34: Spleen

AB-34.1: Spleen  109
AB-34.2: Trauma - Spleen  110
**AB-34.1: Spleen**

- **Incidental splenic findings on US:**
  - CT abdomen (CPT® 74170) or MRI abdomen (CPT® 74183) can be obtained.

- **Incidental splenic findings on CT or MRI:**
  - Imaging is diagnostic of a benign lesion (simple cyst, hemangioma) or characteristics are benign-appearing (homogenous, low attenuation, no enhancement, smooth margins):
    - No follow-up imaging.
  - Imaging characteristics are not diagnostic:
    - Prior imaging available:
      - One year stability: no follow-up imaging
      - Lack of stability: consider MRI if not done, biopsy, or PET/CT (CPT® 78815).
    - No prior imaging:
      - Suspicious imaging features: (suggesting possible malignancy)
        - MRI abdomen (CPT® 74183) if not already done or biopsy
        - If MRI still inconclusive and biopsy is not feasible then PET/CT (CPT® 78815) can be considered
      - Indeterminate imaging features: (equivocal but not suspicious for malignancy)
        - Follow up MRI abdomen (CPT® 74183) in 6 and 12 months.
    - Known malignancy:
      - < 1 cm: follow up MRI abdomen (CPT® 74183) in 6 and 12 months.
      - > 1 cm: consider MRI abdomen (CPT® 74183) if not done, biopsy
        - If MRI still inconclusive and biopsy is not feasible then PET/CT (CPT® 78815) can be considered
      - (See diagnosis-specific in Oncology Imaging Guideline).

- **Clinically detected splenomegaly**
  - Abdominal US (CPT® 76700 or CPT® 76705) should be the first imaging study to evaluate splenic size.
  - If splenomegaly is confirmed, the following evaluation is indicated prior to advanced imaging:
    - CBC, evaluation of the peripheral blood smear, LFTs, UA, CXR, HIV testing.
    - CT Abdomen without and with contrast or with (CPT® 74170 or CPT® 74160) can be performed if the etiology of the splenomegaly remains unexplained.
    - MRI Abdomen (CPT® 74183) can be considered for pregnant individuals, or individuals with iodinated contrast allergy.
AB-34.2: Trauma - Spleen

Ultrasound Abdomen (CPT® 76700 or CPT® 76705) and Pelvis (CPT® 76856 or CPT® 76857) or CT³,⁴,⁵ Abdomen and Pelvis without and with contrast (CPT® 74178) or with contrast (CPT® 74177) are indicated in individuals with blunt abdominal trauma with suspected splenic rupture or in individuals with penetrating trauma to the left upper quadrant. See AB-10: Blunt Abdominal Trauma

Background and Supporting Information

Splenomegaly is usually the result of systemic disease, and diagnostic studies are directed toward identifying the causative disease. Complete blood count with differential, LFT’s, and peripheral blood smear examination are often performed prior to considering advanced imaging. There is no evidence-based data to support performing serial CT or MRI to follow individuals with incidental splenic lesions.

References


### AB-35: Indeterminate Renal Lesion

<table>
<thead>
<tr>
<th>AB-35.1: Indeterminate Renal Lesion</th>
<th>112</th>
</tr>
</thead>
</table>

---

© 2019 eviCore healthcare. All Rights Reserved.  
400 Buckwalter Place Boulevard, Bluffton, SC 29910 (800) 918-8924  
www.eviCore.com
AB-35: Indeterminate Renal Lesion– General Information
For acute flank pain, rule out renal stone, See AB-4: Flank Pain, Rule Out or Known Renal/Ureteral Stone

AB-35.1: Indeterminate Renal Lesion

- Incidental Renal Mass on Non-Contrast CT
  - If characterized as heterogeneous (thick or irregular wall, mural nodule, septa or calcification):
    - Considered indeterminate. MRI abdomen without and with contrast (CPT® 74183) or CT abdomen without and with contrast (CPT® 74170)
  - If characterized as homogenous (thin or imperceptible wall, NO mural nodule, septa or calcification):
    - 10 to 20 HU (Hounsfield units)
      - Likely benign, not fully characterized: no further workup
    - 21 to 69 HU
      - Indeterminate: MRI or CT abdomen without and with contrast (CPT® 74183 or CPT® 74170)
    - >70 HU
      - Hemorrhagic or proteinaceous cyst, unlikely to be neoplastic: no further workup
  - If characterized as TSTC (too small to characterize) and homogenous:
    - If labelled likely benign cyst, not fully characterized:
      - No further workup
    - If labelled inconclusive based on subjective evaluation:
      - Considered indeterminate. MRI abdomen without and with contrast (CPT® 74183) (preferred) or CT abdomen without and with contrast (CPT® 74170) within 6-12 months

- Incidental Renal Mass on Contrast-Enhanced CT
  - If characterized as heterogeneous: thick or irregular wall, mural nodule, septa or calcification:
    - Considered indeterminate. MRI abdomen without and with contrast (CPT® 74183) or CT abdomen without and with contrast (CPT® 74170)
  - If characterized as homogenous: thin or imperceptible wall, NO mural nodule, septa or calcification:
    - 10 to 20 HU
      - No further workup
    - >20 HU (solid or complicated cystic mass
      - Considered indeterminate. MRI abdomen without and with contrast (CPT® 74183) or CT abdomen without and with contrast (CPT® 74170)
  - If characterized as TSTC, homogenous:
    - If labelled likely benign cyst, not fully characterized:
      - No further workup
If labelled inconclusive based on subjective evaluation:
- Considered indeterminate. MRI abdomen without and with contrast (CPT® 74183) (preferred), or CT abdomen without and with contrast (CPT® 74170) within 6-12 months

Incidental cystic renal mass on CT or MRI without and with contrast (completely characterized, and does NOT contain fat)
- Bosniak I (benign simple) or II (minimally complicated)
  - No further workup
- Bosniak IIF
  - CT abdomen without and with contrast (CPT® 74170) or MRI abdomen without and with contrast (CPT® 74183) at 6 and 12 months, then yearly for 5 years
  - If no changes for 5 years, cyst is considered benign and of no clinical significance
- Bosniak III or IV should be referred for additional management or if chosen, active surveillance (See Active Surveillance guideline)

Incidental solid renal mass or incidental mass too small to characterize evaluated on CT or MRI without and with contrast and does NOT contain fat
- TSTC
  - If labelled likely benign cyst:
    - No further workup
  - If labelled inconclusive based on subjective evaluation:
    - MRI abdomen without and with contrast (CPT® 74183) (preferred), or CT abdomen without and with contrast (CPT® 74170) within 6-12 months
- If solid mass <1.0cm
  - MRI abdomen without and with contrast (CPT® 74183) (preferred), or CT abdomen without and with contrast (CPT® 74170) beginning at 6-12 months, then yearly for 5 years
  - If stable at 5 years (average growth ≤3mm per year): No further workup
  - If mass shows growth (≥4mm per year) or morphologic change: refer for management, consider renal biopsy. If biopsy is technically challenging or relatively contraindicated, a T2 weighted image MRI abdomen without and with contrast (CPT® 74183) can be performed
- Solid mass 1.0-4.0cm:
  - Considered a small renal neoplasm: refer for management, consider biopsy. If biopsy is technically challenging or relatively contraindicated, a T2 weighted imaging MRI abdomen without and with contrast (CPT® 74183) can be performed. If active surveillance chosen due to limited life expectancy or co-morbidities, See Active Surveillance guideline.
- Solid renal mass >4.0cm
  - Considered a renal neoplasm: refer for management, or biopsy. If biopsy is technically challenging or relatively contraindicated, a T2 weighted image MRI abdomen without and with contrast (CPT® 74183) can be performed. If active surveillance chosen due to limited life expectancy or co-morbidities, See Active Surveillance guideline
Incidental renal mass containing fat (contains a region of interest measuring < -10 HU)

- No calcification angiomyolipoma (AML)
  - Solitary and without documentation of growth:
    - <4cm: no further workup
    - >4cm, and considered an AML with potential for clinical symptoms: refer for management.
  - Multiple lesions or growth documented based on old studies:
    - Refer for management. If active surveillance chosen due to limited life expectancy or co-morbidities, See Active Surveillance guideline.

- With calcification (suspected renal cell carcinoma):
  - CT abdomen without and with contrast (CPT® 74170) or MRI abdomen without and with contrast (CPT® 74183) if only a non-contrast CT has been performed. If active surveillance chosen due to limited life expectancy or co-morbidities, See Active Surveillance guideline.

Active Surveillance

- If active surveillance is chosen for a suspected or confirmed RCC in an individual with limited life expectancy or high surgical risk due to co-morbidities the schedule is as follows:
  - CT abdomen without and with contrast (CPT® 74170) or MRI abdomen without and with contrast (CPT® 74183) every 3 months for the first year, every 6 months for the second and third years, and then annually

NOTE: PET-CT or PET-MRI are not recommended because their role evaluating the incidental renal mass is limited.¹

Bosniak Classification:

I- Benign simple cyst with a hairline thin wall without septa, calcification, or solid component. Homogeneous near-water attenuation density (10 to 20 HU) without enhancement.

II- Benign minimally complicated cyst that may contain a few hairline thin septa that may have “perceived” but not measurable enhancement. Fine calcification or a segment of slightly thickened calcification may be present in the wall or septa. Also, a well-margined nonenhancing homogeneous mass <3cm with density above simple fluid attenuation (hyperdense cyst).

IIF- Usually benign complicated renal cyst with multiple hairline thin septa or minimal smooth thickening of the wall or septa. Wall or septa may contain thick and nodular calcification and may have “perceived” but not measurable enhancement. Also, a well-margined intrarenal nonenhancing mass >3cm with density above simple fluid.

III -Indeterminate complicated cystic renal mass with thickened irregular walls or septa that have measurable enhancement.
IV-Malignant cystic renal mass with enhancing soft tissue components (cystic renal cell carcinoma).

From the Journal of the American College of Radiology¹

References
AB-36.1: Renal Failure

- Ultrasound (CPT® 76770 or CPT® 76775) kidney and bladder, preferably with Doppler (CPT® 93975 or CPT® 93976), is the preferred imaging study for in the evaluation of acute or chronic renal failure.

- MRA Abdomen (CPT® 74185) when there is suspected:
  - Renal vein/caval thrombosis
  - Renal artery stenosis as cause of renal failure
  - MRA with contrast may be contraindicated in severe renal failure or individuals on dialysis due to the risk of gadolinium agents in causing nephrogenic systemic sclerosis.

- CT Abdomen without contrast (CPT® 74150) is not needed except to rule out ureteral obstruction or retroperitoneal mass.

References


AB-37.1: Renovascular Hypertension

See PVD-6.5: Renovascular Hypertension
AB-38.1: Polycystic Kidney Disease

Ultrasound\(^1\) (CPT\(^\circledast\) 76770 or CPT\(^\circledast\) 76775) can be performed for:

- Suspected polycystic kidney disease
- Screening individuals at risk for autosomal dominant polycystic disease (ADPKD)

Reference

## AB-39: Hematuria and Hydronephrosis

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>AB-39.1</td>
<td>Hematuria with Urinary Tract Infection (UTI)</td>
<td>123</td>
</tr>
<tr>
<td>AB-39.2</td>
<td>Hematuria, not Related to Urinary Tract Infection (UTI) or Flank Pain (Asymptomatic Hematuria)</td>
<td>123</td>
</tr>
<tr>
<td>AB-39.3</td>
<td>Hematuria and Flank Pain (suspicion for renal/urethral stones)</td>
<td>123</td>
</tr>
<tr>
<td>AB-39.4</td>
<td>Hydronephrosis of unexplained or indeterminate cause</td>
<td>124</td>
</tr>
</tbody>
</table>
AB-39.1: Hematuria with Urinary Tract Infection (UTI)

- Females < 40 years of age should receive at least a 3-day regimen of antibiotics followed by repeat dipstick urinalysis or complete urinalysis with microscopic exam. If the hematuria resolves, advanced imaging is not indicated. If symptoms persist, may receive CT Urogram (CPT® 74178).
- CT Urogram¹ (CPT® 74178) for females > 40 years of age
- Males with UTI should be imaged, See AB-40: Urinary Tract Infection (UTI)

**NOTE:** 3-D Reconstruction enhances a CT Urogram. Requests for 3-D reconstruction (CPT® 76377) for a CT Urogram can be approved.

*Background and Supporting Information*

Signs and symptoms of UTI (urinary frequency, burning on urination, positive urine leukocyte esterase, presence of WBCs in the urine, fever, elevated WBC as per the testing laboratory’s range.

AB-39.2: Hematuria, not Related to Urinary Tract Infection (UTI) or Flank Pain (Asymptomatic Hematuria)

- Multiphasic CT Urogram (CPT® 74178)
- If CT contraindicated (renal insufficiency, contrast allergy):
  - MR urography without and with contrast (CPT® 74183 and CPT® 72197) or without contrast
    - if pregnant or contrast contraindicated CPT® 74181 and CPT® 72195
    - If both multiphase CT and MRI are contraindicated:
      - CT urography without contrast (CPT® 74176) or renal US (CPT® 76775 or CPT® 76770) can be approved
- If persistent or recurrent asymptomatic hematuria with an initial negative urologic workup, repeat imaging within 3 to 5 years should be considered.
- **NOTE:** 3-D Reconstruction enhances a CT Urogram. Requests for 3-D reconstruction (CPT® 76377) for a CT Urogram can be approved.

AB-39.3: Hematuria and Flank Pain (suspicion for renal/urethral stones)

- CT Abdomen and Pelvis without contrast (CPT® 74176) or CT Urogram (CPT® 74178)
- **NOTE:** 3-D Reconstruction enhances a CT Urogram. Requests for 3-D reconstruction (CPT® 76377) for a CT Urogram can be approved,
AB-39.4: Hydronephrosis of unexplained or indeterminate cause

CT Urogram (CPT® 74178)

- NOTE: 3-D Reconstruction enhances a CT Urogram. Requests for 3-D reconstruction (CPT® 76377) for a CT Urogram can be approved.

- Individuals with known uncomplicated hydronephrosis, neurogenic bladder, myelomeningocele (open spinal dysraphism), or spina bifida can have follow-up/surveillance imaging with retroperitoneal ultrasound (CPT® 76770) every 6 to 12 months.

References


<table>
<thead>
<tr>
<th>AB-40: Urinary Tract Infection (UTI)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>AB-40.1: Upper (Pyelonephritis)</td>
<td>126</td>
</tr>
<tr>
<td>AB-40.2: Lower</td>
<td>126</td>
</tr>
</tbody>
</table>
**AB-40: Urinary Tract Infection**

These guidelines refer to UTI without Hematuria. For UTI with Hematuria, See **AB-39: Hematuria and Hydronephrosis**

**AB-40.1: Upper (Pyelonephritis)**

- CT Abdomen and Pelvis without and with contrast (CPT® 74178) or CT Abdomen and Pelvis with contrast (CPT® 74177) if:
  - Suspected complicated: diabetes, immune-compromised, history of stones, prior renal surgery, elevated creatinine, or fever ≥ 101 F (≥ 38.5 C).
  - Not responding to therapy after 3 days.
  - Recurrent pyelonephritis (at least 1 prior pyelonephritis).
  - Males with first time UTI, or recurrent UTI without etiology.

- Pregnant women should be evaluated initially by renal ultrasound (CPT® 76770 or CPT® 76775) and if further imaging is necessary, MRI Abdomen and Pelvis (contrast as requested).

**AB-40.2: Lower**

- CT Abdomen and Pelvis without and with contrast (CPT® 74178) if:
  - Suspected complicated: diabetes or immunocompromised or history of stones or prior renal surgery, elevated creatinine or fever ≥ 101 F (≥ 38.5 C).
  - Not responding to therapy after 3 days.
  - Males with first time UTI or recurrent UTI without etiology.
  - Recurrent UTI > 3 per year.
  - Recommendation by urologist or specialists.


**References**

AB-41.1: Patent Urachus

- See PV-23.1 Patent Urachus in the Pelvis Guideline
<table>
<thead>
<tr>
<th>AB-42: Transplant</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>AB-42.1: Liver Transplant, Pre-Transplant</td>
<td>130</td>
</tr>
<tr>
<td>AB-42.2: Liver Transplant, Partial Liver Transplant Donors</td>
<td>130</td>
</tr>
<tr>
<td>AB-42.3: Liver Transplant, Post-transplant</td>
<td>131</td>
</tr>
<tr>
<td>AB-42.4: Liver Transplant, Post-Transplant Lymphoproliferative Disease (PTLD)</td>
<td>131</td>
</tr>
<tr>
<td>AB-42.5: Kidney Transplant, Pre-Transplant Imaging Studies</td>
<td>132</td>
</tr>
<tr>
<td>AB-42.6: Kidney Transplant, Post-transplant</td>
<td>132</td>
</tr>
<tr>
<td>AB-42.7: Heart Transplant</td>
<td>132</td>
</tr>
</tbody>
</table>
AB-42.1: Liver Transplant, Pre-Transplant

- See CD-1.6: Transplant Individuals in the Cardiac Imaging Guidelines for guidelines on cardiac stress testing.

- Individuals on the liver transplant waiting list can undergo advanced imaging per the participating institution’s protocol, as long as the studies do not exceed the following:
  - If no known Hepatocellular Carcinoma:\n    - Liver ultrasound (CPT® 76705) with Doppler (CPT® 93975) every six months.
    - CT or MRI Abdomen (CPT® 74170 or CPT® 74183) every year.
    - CT chest (CPT® 71260) for initial placement on the transplant list, but repeat chest CT is not required.
    - MRI Bone Marrow Blood Supply (CPT® 77084) or bone-scan one time.
  - If known Hepatocellular Carcinoma\textsuperscript{1,2}:
    - Liver ultrasound (CPT® 76705) with Doppler (CPT® 93975) every six months.
    - CT or MRI Abdomen (CPT® 74170 or CPT® 74183) every three months.
    - CT Chest (CPT® 71260) every six months.
    - Bone scan every six months.
  - If known Primary Sclerosing Cholangitis\textsuperscript{1} (PSC)
    - MRCP (See AB-27: MR Cholangiopancreatography (MRCP) for correct reporting/coding)

- Pre-operative studies \textbf{immediately prior} to liver transplant\textsuperscript{3}:
  - CT or MRI Abdomen (CPT® 74170 or CPT® 74183)
    - If CT Abdomen was most recently done while on the transplant waiting list, then MRI Abdomen should be done immediately prior to transplant and vice versa.
  - CT Pelvis (CPT® 72193)
  - CTA Abdomen (CPT® 74175) or MRA Abdomen (CPT® 74185)
  - CT Chest (CPT® 71260)
  - MRI Bone Marrow Blood Supply (CPT® 77084) or bone scan

AB-42.2: Liver Transplant, Partial Liver Transplant Donors

- CT of the Abdomen without and with contrast (CPT® 74170) or MRI of Abdomen without and with contrast (CPT® 74183) prior to transplant to evaluate donors for partial liver transplant.
AB-42.3: Liver Transplant, Post-transplant

See CD-1.6: Transplant Individuals in the Cardiac Imaging Guidelines for guidelines on stress testing.

- If known hepatocellular carcinoma (i.e. transplant performed for treatment of HCC, or if a de novo HCC is discovered in the explant liver):
  - CT Abdomen (CPT® 74160 or CPT® 74170) every 6 months for 3 years.
  - CT chest (CPT® 71260) every 6 months for 3 years.

- If no history of hepatocellular carcinoma, but cirrhosis develops in the explant liver:
  - See AB-26: Cirrhosis and Liver Screening for Hepatocellular Carcinoma (HCC); Ascites and Portal Hypertension for HCC screening guidelines

- For fibrosis assessment post-liver transplant:
  - Transient Elastography (this is the most studied modality in this setting)
  - See AB 45: Liver Elastography

- If known cholangiocarcinoma:
  - Liver US (CPT® 76705) or MRI Abdomen and MRCP (CPT® 74183) every 6 months for 5 years post-transplantation.
  - CT chest (CPT® 71260) every 6 months for 5 years post-transplantation

- All other post-transplant individuals:
  - Routine screening of the chest or abdomen is not supported in the absence of HCC.
  - Bone mineral density yearly for individuals with known osteopenia and every 2 to 3 years in individuals with a normal bone mineral density.
  - Advanced imaging as indicated for suspected post-operative complications

Background and Supporting Information

- Consensus guidelines regarding post-transplant surveillance imaging have not yet been established. Guidelines are based on a reasonable approach and are in accordance with suggestions by the American Association for the Study of Liver Diseases (AASLD) and others.

AB-42.4: Liver Transplant, Post-Transplant Lymphoproliferative Disease (PTLD)


- Chest/Abdomen/Pelvis CT with contrast (CPT® 71260 and CPT® 74177) can be performed. Biopsy of the involved organ should be performed if PTLD is suspected.

- There is insufficient evidence-based data to support the routine use of imaging to screen for PTLD.
Background and Supporting Information

Most cases of PTLD are observed in the first year following transplant. Frequency of developing PTLD:

- Small bowel transplant—20% of individuals are at risk of developing PTLD
- Lung transplant—10% risk
- Heart transplant—6% risk
- Liver transplant—1%-3% risk
- Kidney transplant—1%-3% risk

AB-42.5: Kidney Transplant, Pre-Transplant Imaging Studies

See CD-1.6: Transplant Individuals in the Cardiac Imaging Guidelines for guidelines on cardiac stress testing.

Individuals on the kidney transplant waiting list can undergo advanced imaging per that institution’s protocol as long as the studies do not exceed the following:

- Diagnostic left heart catheterization if stress test is positive for reversible ischemia, or if duration of diabetes is > 25 years and individual has additional cardiac risk factors.
- Carotid duplex study (CPT® 93880 bilateral study or CPT® 93882 unilateral study) if there is history of stroke, TIA, or if carotid bruit is present on exam.
- CT Abdomen and Pelvis (CPT® 74176 or CPT® 74177) or CTA Abdomen (CPT® 74175) one time.

AB-42.6: Kidney Transplant, Post-transplant

Ultrasound of transplanted kidney:

- Current ultrasound imaging protocols of the transplanted kidney commonly include a Doppler study and are coded as CPT® 76776.
  - Do not report non-invasive vascular codes CPT® 93975 and CPT® 93976 in conjunction with CPT® 76776.
- Ultrasound of the transplanted kidney performed without duplex Doppler should be reported as a limited retroperitoneal ultrasound (CPT® 76775).

AB-42.7: Heart Transplant

See CD-1.6: Transplant Individuals in the Cardiac Imaging Guidelines
References


## AB-43: Hepatic and Abdominal Arteries

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>AB 43.1: Hepatic Arteries and Veins</td>
<td>135</td>
</tr>
<tr>
<td>AB 43.2: Abdominal Veins other than Hepatic and Portal Veins</td>
<td>135</td>
</tr>
<tr>
<td>AB 43.3: Renal Vein Thrombosis</td>
<td>135</td>
</tr>
</tbody>
</table>
AB 43.1: Hepatic Arteries and Veins

- CTA Abdomen and Pelvis (CPT® 74174), or CTA Abdomen (CPT® 74175) or MRA Abdomen (CPT® 74185) if ONE of the following:
  - Evaluation of portal and hepatic veins prior to or following TIPS (transjugular intrahepatic portosystemic shunt)
  - Evaluation of portal and hepatic veins prior to or following surgical intervention for portal hypertension
  - Evaluation of hepatic vasculature prior to and following embolization procedure
  - Evaluation of hepatic vasculature prior to planned hepatectomy
  - Evaluation of liver donor
  - Suspected hepatic vein thrombosis or Budd Chiari syndrome, ONE of the following:
    - Ascites
    - Hepatomegaly
    - Inadequate Doppler ultrasound of hepatic veins
  - Possible portal vein thrombosis with negative or inadequate Doppler study of the portal vein, ONE of the following:
    - Hypercoagulable state
    - Abdominal malignancy
  - Preoperative evaluation for pancreatic cancer

AB 43.2: Abdominal Veins other than Hepatic and Portal Veins

- CTA Abdomen and Pelvis (CPT® 74174), or CTA Abdomen (CPT® 74175) or MRA Abdomen (CPT® 74185) if ONE of the following:
  - Nephrotic syndrome
  - Suspicion of iliac vein thrombus
  - Suspicion of inferior vena cava thrombus
  - Renal vein thrombosis
  - Mesenteric vein thrombosis

AB 43.3: Renal Vein Thrombosis

- MRA Abdomen (CPT® 74185) if ONE of the following:
  - Nephrotic syndrome
  - Proteinuria – 3 grams or more in 24 hours
  - Lupus nephritis
  - Hypercoagulable state, one of the following:
    - Antiphospholipid antibodies
    - Behçet’s syndrome
    - Protein C deficiency
    - Protein S deficiency
References


AB-44: This section intentionally left blank
Vibration-Controlled Transient Elastography (VCTE) (e.g. Fibroscan, CPT® 91200) may be considered appropriate to assess for advanced fibrosis and cirrhosis in the following conditions:
- Hepatitis C
- Hepatitis B
- Chronic alcoholic liver disease
- All other chronic liver diseases

If requested, Magnetic Resonance Elastography of the liver (MRE, CPT® 76391) can be approved for:
- Non-alcoholic fatty liver disease (NAFLD) in high risk (for cirrhosis) populations:
  - Advanced age (65 years old or greater)
  - Obesity (BMI 30 or higher)
  - Diabetes
  - ALT > 2X upper limit of normal
- For NAFLD in low risk populations (e.g. signs of fatty liver found on imaging only, without the above-noted risk factors) MRE would be considered investigational.

The use of VCTE and MRE are considered experimental and investigational for all other indications with regards to liver disease.

The use of other ultrasound elastographic techniques (CPT® 76981, CPT® 76982, and CPT® 76983), including but not limited to acoustic radiation force impulse imaging or real-time tissue elastography for any indication is considered experimental or investigational at this time.

Background and Supporting Information
For the assessment of cirrhosis in individuals with hepatitis C, the AGA noted that MRE has little to no increase in identifying cirrhosis, but had poorer specificity and thus higher false-positive rates than VCTE. In view of this, the AGA concluded that MRE has a poorer diagnostic performance in this setting, compared to VCTE. In their recommendations for the assessment of fibrosis in chronic liver disease, VCTE was recommended over MRE with the exception of NAFLD in high risk populations, in which MRE resulted in a lower rate of false positives compared to VCTE. In low risk populations with NAFLD, both MRE and VCTE performed poorly, and their role is as yet, undefined.

Reference